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ABSTRACT
INVESTIGATIONS OF N-ACETYLTRANSFERASES IN
HUMAN HEPATOCYTES AND RAT MODELS
Jason M. Walraven
March 4, 2005
This thesis begins by reviewing human N-acetyItransferases (Chapter I), then outlines
experiments involving human hepatocytes and rat N-acetyltransferases (Chapters II-V). These
experiments facilitated the development of a dissertation project designed to study Nacetyltransferase tissue-specific expression in inbred rat strains (Chapter VI).
Real-time PCR experiments concluded that genetic and/or environmental factors
influence N-acetyItransferase expression in cryopreserved human hepatocytes.
animal model must be used to study N-acetyItransferase expression.

Therefore, an

Initial studies of

recombinantly expressed rat N-acetyltransferases (Nats) revealed a correlation between rat and
human N-acetyltransferases in nucleotide and amino acid sequence, catalytic activity, substrate
selectivity and thermostability, suggesting the rat is an acceptable model for such studies.
Dissertation aims outlined for studying rat N-acetyltransferase expression in tissues of various
inbred rat strains involve analysis of tissue-specific mRNA splicing, mRNA expression, protein
expression, and enzyme activity, and a study of cigarette smoke inhalation as a possible
environmental influence on Nat expression.

IV

TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS ........................................................................................................ iii
ABSTRACT ................................................................................................................................ iv
LIST OF FIGURES .................................................................................................................... vii
CHAPTER
I. BACKGROUND AND SIGNIFICANCE ..................................................................... 1
II. NATl EXPRESSION IN PRIMARY HUMAN HEPATOCYTES ............................... 15
Introduction ............................................................................................................. 15
Methods ................................................................................................................... 20
Results & Discussion ............................................................................................... 25
Conclusions ............................................................................................................. 36
Future Experiments ................................................................................................. 37
III. A RODENT MODEL FOR STUDYING N-ACETYLTRANSFERASE TISSUESPECIFIC EXPRESSION IN VIVO .............................................................................. 38
IV. IDENTIFICATION, CLONING, AND SEQUENCING OF A NOVEL RAT NACETYLTRANSFERASE GENE (NA T3) ................................................................... 41
Introduction ............................... '" .......................................... '" .............................. 41
Methods ................................................................................................................... 43
Results & Discussion ............................................................................................... 44
V. CHARACTERIZATION OF RAT N-ACETYLTRANSFERASES NATl*I3, NAT2*20,
NAT2*2IA, NAT2*2IB, AND NAT3 BY CLONING AND RECOMBINANT
EXPRESSION IN ESCHERICHIA COLI ...................................................................... 49
Introduction ............................................................................................................. 49
Methods ................................................................................................................... 52
Results & Discussion ............................................................................................... 60

v

Conclusions ............................................................................................................. 81
Future Experiments ................................................................................................. 83
VI. TISSUE-SPECIFIC EXPRESSION OF RAT N-ACETYLTRANSFERASES:
DISSERTATION AIMS AND EXPERIMENTAL METHODS ................................... 84
Introduction ............................................................................................................. 84
Specific Aim I. ......................................................................................................... 85
Introduction ............................................................................................. 85
Methods ................................................................................................... 85
Specific Aim II ........................................................................................................ 88
Introduction ........................................................... '" ............................... 88
Methods ................................................................................................... 90
Specific Aim III ....................................................................................................... 102
Introduction ............................................................................................. 102
Methods ................................................................................................... 102
REFERENCES ............................................................................................................................ 106
APPENDIX ................................................................................................................................. 119
CURRICULUM VITAE ............................................................................................................. 122

VI

LIST OF FIGURES
PAGE

FIGURE

I. Chemical Structures of Some N-acetyltransferase Substrates .............................................. 2
2. Reactions Catalyzed by Arylamine N-acetyltransferases ..................................................... 4
3. Cryopreserved Hepatocyte NATl and NAT2 GenotypelPhenotype Correlation ................... 16
4. Real-Time PCR of NATl*4 and NATl*lO Allele cDNA ..................................................... 21
5. Quantitative Real-Time RT-PCR Sensitivity for NATl Allele Expression Analyses .......... 26
6.

NA Tl Allelic Expression in NA Tl *41* 10 Human Hepatocytes ........................................... 27

7. Hepatocyte NAT I Activity and NATl mRNA Expression .................................................. 29
8. Creation of a Standard Curve with NATl*41*4 & NATl*lOI*1O Genomic DNA
Mixtures ................................................................................................................................ 31
9.

Standard Curve Analysis of Hepatocyte NATl Allelic Expression ...................................... 33

10. Rat Nat3 Nucleotide and Deduced Amino Acid Sequences ................................................. 45
II. Amino Acids 125, 127, 129 Influence N-acetyltransferase Substrate Selectivity ................ 46
12. Human, Mouse, and Rat N-acetyltransferase Sequence Homologies .................................. 47
13. Peptide Design Strategy for Nat3-specific Polyclonal Antibody Development.. ................. 58
14. Rat Nat N-acetylation of PABA and SMZ ........................................................................... 61
15. Rat Nat N-acetylation of MDA and MOCA ........................................................................ 62
16. Rat Nat N-acetylation of ABP and AF ................................................................................. 63
17. Rat Nat N-acetylation ofpABG ........................................................................................... 64
18. Kinetics of Rat Nat N-acetylation of 2-Arninofluorene ........................................................ 67
19. Kinetics of Rat Nat N-acetylation of 4-Aminobiphenyl... .................................................... 68
20. Thermostability of Recombinant Rat N-acetyltransferases .................................................. 70

V\1

21. Polyclonal Antisera Detection of Rat N-acetyltransferases by Western blot ....................... 72
22. Immunoreactive Detection of Recombinantly Expressed Rat Nat2 Enzymes ...................... 74
23. Real-time RT-PCR Analysis of RecombinantIy Expressed Rat Nat2 mRNA ...................... 75
24. Constructed Sequence of Recombinant Nat mRNA from PKK223-3 .................................. 78
25. Mfold Predicted mRNA Structures for Recombinant Nat2 Slow Alleles ............................ 79
26. Taqman Primer and MGB Probe Design for RT-PCR Rat Nat Locus Discrimination ........ 95
27. Primer Design for Real-Time PCR Controls and PCR of RACE Products .......................... 97

Vlll

CHAPTER I
BACKGROUND AND SIGNIFICANCE

Arylamine N-acetyltransferases NATI and NAT2 are xenobiotic metabolizing enzymes
that first received attention over 40 years ago when researchers discovered that polymorphic
NAT2 modifies individual human variability in the metabolism of the anti-tubercular drug

isoniazid (Evans et aI., t 960; Peters et aI., 1965), making N-acetyltransferases among the first
polymorphic genes identified.

It was later discovered that this role extended also to other

hydrazine drugs including the MAO inhibitor phenelzine and the anti-hypertensive drug
hydralazine (Lemke et aI., 1995; Weber and Hein, 1985). NATs also detoxify the antibacterial
sulfonamides (Parker, t 969) and arylamine drugs such as the antiarrhythmic drug procainamide,
the antibiotic dapsone, and the aromatase inhibitor aminoglutethimide (Weber and Hein, 1985)
(Figure 1).
The human genome encodes two active N-acetyltransferase isoforms, NAT! and NAT2,
each consisting of a single intronless coding exon 870 base pairs long. These genes lie in close
proximity on chromosome 8 (Matas et aI. 1997), with high nucleotide sequence identity (86.8%),
and which encode proteins that share a high amino acid sequence identity (80.0%). Human
NAT 1 and NAT2 enzymes are very similar in their sequence and function, with distinct, yet
overlapping, substrate selectivities, distinct structural stabilities, and distinct kinetic properties
toward their arylamine substrates (Blum et aI., 1990; Hein et ai, 1993).
In addition to drug detoxification, NATs are implicated as modifiers of cancer

predisposition due to their roles in both detoxification and activation of aromatic and heterocyclic
amine carcinogens in the environment (Fretland et aI., 2002). NATs metabolize carcinogens like
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Figure 1. Chemical Structures of Some N-acetyltransferase Substrates.
N-acetyltransferase (NAT) isozymes metabolize aromatic amines, heterocyclic amines, and
hydrazines,

including

many

pharmaceutical

drugs

and

environmental

carcinogens.

(A)

Some

pharmaceutical drugs metabolized by NATs include the antitubercular drug isoniazid, the antihypertensive
drug hydralazine, the MAO inhibitor phenelzine, the aromatase inhibitor aminoglutethimide, the antibiotic
dapsone, the antiarrhythmic drug procainamide, and the antibacterial drug sulfamethazine.

(B) Some

environmental carcinogens metabolized by NATs include 4-aminobiphenyl (ABP), a component of
cigarette smoke, and 2-amino-I-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), found in meats cooked
well-done.
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4-aminobiphenyl (ABP), a component of cigarette smoke (Patrianakos et aI., 1979), the
carcinogen 2-amino-l-methyl-6-phenylimidazo[4,5-b ]pyridine (PhIP), and other protein pyrolysis
products, formed in meats cooked well-done (Godshalk et aI., 2001; Layton et aI., 1995). Prior to
acting as mutagens and animal carcinogens, these compounds must first undergo metabolic
activation by xenobiotic metabolizing enzymes (Wogan et aI., 2004).
N-acetyltransferases catalyze N-acetylation (usually detoxification), O-acetylation
(activation), and N,O-acetylation (activation) reactions (Hein DW, 1988). These reactions are
carried out via a ping-pong reaction mechanism in which the NAT enzymes use acetyl-CoA as
the acetyl-group donor (Riddle and Jencks, 1971). All N -acetyitransferases, regardless of species,
contain the Cys-His-Asp catalytic triad, which resembles that of cysteine proteases (Sinclair et aI.,
2000). NATs catalyze N-acetylation (Figure 2) by transferring an acetyl group from acetyl-CoA
to the exocyclic nitrogen of an aromatic or heterocyclic amine. This is usually a detoxification
step, leading to excretion of the metabolite.

For O-acetylation (Figure 2) to take place, the

exocyclic amine must first undergo N-hydroxylation by a CYPIAI or CYP1A2 enzyme. This
reaction competes with N-acetylation for the exocyclic nitrogen, and is considered an activation
step. N-acetyitransferases will further activate the carcinogen by transferring an acetyl group to
the oxygen. The resulting N-acetoxy metabolite is very unstable and spontaneously decomposes
to acetic acid and a highly reactive arylnitrenium ion. This electrophilic ion will then form
adducts with nucleophilic sites throughout the ceil, including DNA and proteins. N,O-acetylation
(Figure 2) is similar to O-acetylation except that the competing N-acetylation and Nhydroxylation reactions both succeed, result in an N-acetylated and N-hydroxylated exocyclic
nitrogen. NATs can then catalyze intramolecular O-acetylation, resulting in the same unstable
acetoxy species formed by O-acetylation (Hein DW, 1988).
Because NAT! and NAT2 are highly polymorphic, they contribute to individual cancer
susceptibility by modifying the activation and deactivation of arylamine carcinogens.

To date,

over 25 known human NAT! alleles and over 35 known human NAT2 aIIeIes have been identified,
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Figure 2. Reactions Catalyzed by Arylamine N-acetyltransferases
N-acetylation occurs when an acetyl group is transferred from acetyl-CoA to the exocyclic
nitrogen of an aromatic or heterocyclic amine, and is usually a detoxification step. P450 enzymes compete
with NATs for metabolism of the exocyclic nitrogen where they catalyzing a hydroxylation reaction,
thereby activating the carcinogen. NATs can further activate the compound by subsequently acetylating
the oxygen which results in an extremely unstable N-acetoxy derivative.

The N-acetoxy form of the

molecule spontaneously breaks down to form an electrophilic arylnitrenium ion which can form adducts
with DNA and other nucleophilic sites in the cell. Alternatively, the exocyclic nitrogen can be both Nacetylated and N-hydroxylated, in which case NATs will catalyze an intramolecular transfer of the acetyl
group to the oxygen, resulting in formation of the reactive arylnitrenium ion.
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each of which possess a combination of single nucleotide polymorphisms (SNPs) (Vatsis et aI.,
1995). Some of these SNPs modify the acetylator phenotype of an individual by altering enzyme
stability, enzyme function, and/or mRNA expression, resulting in rapid, intermediate, and slow
acetylator phenotypes (Butcher et ai., 2002; Fretland et ai., 2001 alb; Leff et ai., 1999a; Zang et
aI., 2004). The fact that these enzymes are highly polymorphic makes them a prime research
subject for molecular epidemiology studies, from which we can gain insight into how different
allelic forms of these enzymes can modify an individual's cancer risk, drug response, and the
susceptibility to adverse drug reactions (Rein et ai., 2000b; Spielberg, 1996).

While the

xenobiotic metabolizing function of NATs applies to pharmaceutical drugs and carcinogens, as
covered above, this review will focus on the role of NATs in carcinogen metabolism and cancer
susceptibility.
Molecular epidemiology studies that have investigated the relationship between Nacetyltransferase genotype/phenotype and cancer risk suggest that NATs modify predisposition to
various cancers. Such studies have investigated the role of polymorphic NAT variants in urinary
bladder cancer (Cartwright et aI., 1982; Lower et ai., 1979), colorectal cancer (Bell et ai., 1995a;
Chen et ai., 1998), breast cancer (Bulovskaya et ai., 1978; Millikan et ai., 1998), lung cancer
(Cascorbi et ai., 1996; Bouchardy et aI., 1998), head and neck cancer (Gonzalez et aI., 1998;
Olshan et aI., 1997), prostate cancer (Fukutome et ai, 1999; Wade1ius et ai., 1999), pancreatic
cancer (Bartsch et ai., 1998), and others. Some of these studies suggest a positive correlation
between certain NAT genotypes and predisposition to cancer. In general, however, the findings
of these epidemiological studies are inconsistent. Apparent inconsistencies may be attributable to
the study of different chemical carcinogens, inadequate understanding of the genotype/phenotype
relationship of some alleles, small sample size, and/or other confounding factors not accounted
for in the study design (Rein et ai., 2000a).

The most consistently reported molecular

epidemiological associations indicate that individuals with a NAT2 slow acetylator phenotype are
at higher risk for urinary bladder cancer (Cartwright et ai., 1982; Lower et ai., 1979), due to
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decreased detoxification (N-acetylation) of aromatic amines, and individuals with a NAT2 rapid
acetylator phenotype have an elevated risk for developing colon cancer (Gil and Lechner, 1998;
Ilett et aI., 1987), due to increased activation (O-acetylation) of heterocyclic amines. While we
know little about the role of NATl and NAT2 in cancer susceptibility, we know less about the role
of NAT! (Hein, 2002). This lack of understanding regarding NAT! could be due to an incomplete
understanding of the relationship between NAT! genotype and phenotype, and the factors that
influence this relationship (Hughes et aI., 1998; Butcher et aI., 1998). Although such ambiguity is
observed for some NAT2 alleles, it is to a lesser extent than for NA T! (Gross et aI., 1999; Meisel
et aI., 2001; Sim et aI., 2000).
The epidemiological observation that NAT influence on cancer risk varies depending on
tissue type, as mentioned above, could be explained in various ways. One possible explanation
worth considering involves the tissue-specific regulation of NAT isozymes. This could easily
account for the differences in susceptibility of different tissues to NAT2-mediated carcinogenesis.
Tissue-specific expression could be key to the physiological function of N-acetyltransferases, and
therefore also an important factor influencing the ability of physicians to predict tissue-specific
cancer risk following aromatic amine exposure. NAT! and NAT2 tissue-specific expression could
play an important role in arylarnine-induced cancer risk by determining the ratio of inactive to
reactive arylarnine metabolites within each cell (Grant et aI., 2000), thus modifying the risk of
mutagenesis.
The relative expression of NATI and NAT2 in different tissues is important because
NATI and NAT2, while similar in many ways, differ in several important aspects. First, NATI
and NAT2 have different substrate preferences (Hein et aI., 1994; Minchin et aI., 1992; Wild et
aI., 1995). Although there is some overlap, most substrates are preferentially metabolized by one
isozyme over the other. For instance, human NATl selectively acetylates p-aminobenzoic acid
(PABA), whereas human NAT2 selectively acetylates sulfamethazine (SMZ) (Grant et aI., 1991).
Substrate selectivity is influenced by three key residues in the NAT genes, at positions 125, 127,
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and 129, all three of which differ between NATI and NAT2 (Goodfellow et aI., 2000). Since
NAT 1 is catalytically more efficient than NA T2 (Grant et aI., 1997; Vatsis et aI., 1995; Vatsis and
Weber., 1997), the pool of activated or deactivated carcinogens in a tissue following any given
arylamine exposure is dependent on whether NATl or NAT2 or both are expressed and active in
that tissue, and at what level they are expressed. For example, a high-NAT I-expressing tissue
with barely detectable NAT2 expression may be more at risk from exposure to a NATI selective
carcinogen than a NAT2 selective carcinogen. In addition to substrate selectivity, NATI and
NAT2 differ in structural stability, where NAT2 is much more stable than NATI (Dupret et aI.,
1994).

This difference, detected experimentally as thermostability, could translate into

differences in cellular enzyme turnover. Lastly, differential expression of NAT I and NAT2 in
tissues is important because the catalytic efficiency of the enzymes differs, where NAT I
generally catalyzes reactions much more efficiently than NAT2 (Grant et aI., 2000). Therefore,
considering the differences between NATI and NAT2 in substrate selectivity, structural stability,
and catalytic activity, the tissue-specific expression of these isozymes must be better understood
if we are to advance our understanding of NAT-mediated cancer risk in vivo.
Tissue-specific gene expression is common in the human genome (Bulun et aI., 2003;
Shmelkov et aI., 2004; Simpson, 2004; Whetstine et aI., 2002), and therefore it is reasonable to
suspect that N-acetyltransferase expression might be regulated likewise. While apparent tissueselective epidemiological associations could be explained away by alternative hypotheses, other
data lend support to the idea that NATI and NAT2 are tissue-specifically and cell-typespecifically expressed, though mRNA and protein expression analyses in a wide range of tissues
have yielded inconsistent results (Hickman et aI., 1998).
Unfortunately, NAT protein expression analyses and NAT mRNA expression analyses
have not produced consistent conclusions regarding the sites of NATI and NAT2 expression.
Analyses of NAT protein activity in tissues conclude that NATI is ubiquitously expressed
(Pompeo et aI., 2002; Rodrigues-Lima et aI., 2003), while NAT2 expression is limited to liver
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(Evans and White, 1964) and intestinal epithelium (Hickman et ai., 1998). On the other hand,
NATl and NAT2 transcripts were detected in most tissues using in situ hybridization (Debiec-

Rychter et ai., 1999; Windmill et aI., 1997), suggesting that both NA Tl and NAT2 mRNA are
ubiquitously expressed. Several factors contribute to the apparent discrepancies between analyses
of protein and mRNA expression.
First, mRNA detection methods and protein detection methods differ with regard to
sensitivity. In situ hybridization is a highly sensitive technique capable of detecting even low
levels of transcript (Wilson et ai., 1997), while measurements of enzyme activity are generally
less sensitive. Thus, NATl and NAT2 mRNA are more readily detected than the NATI and
NAT2 enzyme activity.
Second, flaws in experimental design may produce false and confusing results. Correct
probe design is crucial for accurate mRNA detection. This point becomes apparent when
considering the example of conflicting intestine NAT expression reports. It was concluded based
on NAT enzyme acetylation activity measurements that NATl is expressed higher than NAT2 in
the intestine (Hickman et aI, 1998), while mRNA expression analysis suggested that NAT2 is
expressed even higher than NATl (Windmill et aI., 1997). A careful examination of the methods
reveals that the NATI probes were designed to target to a DNA sequence 5' of the NATl start
codon, which is a sequence that may not exist in most NATl transcripts.

Although this 5'

sequence comes from a previously reported NATl transcript (Ohsako and Deguchi, 1990), its
presence in NATl mRNA transcripts is questionable.

Recent analyses of NATl promoters

(Butcher et aI., 2004b; Husain et ai., 2004) do not report this transcript as having even a minor
presence among NATl transcripts. Perhaps NATl expression only appears to be lower than NAT2
expression in Windmill's mRNA staudy because the NATl probe recognizes only small fraction
of NAT I transcripts at best.
A final factor deserving consideration regarding discrepancies between protein and
mRNA expression measurements involves the often difficult and/or misleading interpretation of
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NATI and NAT2 enzyme activity data. For instance, in muscle NAT2 mRNA was detected but
NAT2 enzyme activity was below the limit of detection; on the other hand, NATl mRNA enzyme
were readily detected (Rodrigues-Lima et aI., 2003). Detection of NAT! enzyme but not NAT2
enzyme could be attributed to higher NATI catalytic activity for its selective substrates as
compared to that of NAT2 for its selective substrates. This would permit detection of lower
levels of NAT I by enzymatic activity measurements than similarly low levels of NAT2 (Grant et
aI., 2000).

Detection of low enzyme levels using activity assays is problematic, requiring

relatively high enzymatic activity. In the example above from muscle tissues, the NAT2 activity
level may have fallen below the detection limit, due to its relatively low activity.
The lack of consistent data regarding the tissue-specific expression of NATl and NAT2
precludes coming to meaningful conclusions about how NA Tl and NAT2 are expressed in the
different tissues of the body. A more practical approach must be devised. Understanding how
NAT mRNA expression, protein expression, and enzyme activity are regulated has value for
advancing our understanding of how NA T I and NAT2 tissue-specific expression relates to NA T I
and NAT2 phenotype in different tissues. Analyzing only one of these factors alone, however, has
little practical value. Due to the possibility that post-transcriptional regulation events modify
NAT expression, NA Tl and NAT2 mRNA levels cannot be used as an accurate predictor of NAT
phenotype in a tissue. Likewise, due to the possibility that post-translational regulation events
modify NAT expression, NATl and NAT2 protein levels cannot be used as an accurate predictor
of NAT phenotype in a tissue (since it may be that not all NAT protein is active). Also, it is
possible that these forms of regulation vary widely from tissue to tissue and cell-type to cell-type,
so that it is faulty to assume that the relative levels mRNA expression, protein expression, and
enzyme activity will be in the same proportion in different tissues.

Aside from the method

difficulties discussed above, the fundamental weakness of the studies to-date with regard to their
ability to contribute useful information regarding NAT tissue-specific expression is the mistake of
analyzing only one measure of NAT expression at a time. No study reported to date provides
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concrete data regarding how NATl and NAT2 tissue-specific expression influences NAT
phenotype in tissues because no study to date has analyzed NAT mRNA, protein, and enzyme
activity concurrently in different tissues. This type of study is needed for a more complete
picture of the translational, transcriptional and post-transcriptional influences on NATl and NAT2
expression, and how they might vary among different tissues.
Recent analyses of NATl mRNA structure, and continued studies of NAT induction
suggest that NATl expression is transcriptionally regulated. (Butcher et aI., 2003; Boukouvala et
aI., 2003; Mitchell and Warshawsky, 2003; Zaher and Svensson, 1994).

Identification and

characterization of the major NATl promoters and non-coding exons in human breast
demonstrated the presence of at least 4 alternative NATl promoters (Butcher et aI., 2004b; Husain
et aI., 2004), which could be key to the mechanism by which NAT tissue-specific expression is
regulated (Boukouvala et aI., 2003; Rodrigues-Lima and Dupret, 2004). These studies have also
demonstrated that alternative splicing of the 9 NATl non-coding exons results in at least 7
different mRNA species, with a single dominant promoter in breast tissue. Many mammalian
genes are tissue-specifically expressed through promoter-dependent alternative splicing of noncoding exons, resulting in multiple mRNA species with different transcriptional and translational
efficiencies (Bulun et aI., 2003; Shmelkov et aI., 2004; Ayoubi and Van De Ven, 1996; Whetstine
et al. 2002). Since our knowledge of NATl mRNA structure and expression is limited to a single
tissue in humans (breast), much work remains to be done for other tissues. Also, much remains to
be delineated with regard to these possible expression mechanisms, requiring further study of
NAT] and NAT2 promoter usage and mRNA splicing patterns in multiple tissues. In addition to

an advanced understanding of NAT expression, promoter analyses may provide a foundation for
discovery of an endogenous role for N-acetyltransferases by providing links to biomolecular
signaling pathways involved in NAT expression.
Inconsistent molecular epidemiology data regarding the association of NATl and NAT2
genotype and cancer risk, combined with an unclear relationship between NATl genotype and
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phenotype suggest that our understanding of the factors (other than NAT! and NAT2 SNPs) that
influence acetylator phenotype is incomplete.

Environmental and other genetic factors may

influence acetylator phenotype and arylamine-induced cancer risk (Butcher et aI., 2000b; Husain
et aI., 2004). Advancing our understanding of NAT-mediated cancer risk through successful
molecular epidemiology investigations requires consideration of these other possible influences
on NAT I and NAT2 tissue-specific expression.
The literature reviewed above suggests that these factors probably influence NATI
expression nearly exclusively, considering the observed divergence of NAT! genotype and
phenotype, and the consistent NAT2 genotype and phenotype correlations. Some have postulated
that the apparent lack of correlation between NA T! genotype and phenotype is due to an
incomplete knowledge of NAT! polymorphisms, which would be resolved once a more
comprehensive list of NA T! polymorphisms is compiled (Payton and Sim, 1998). Others suggest
that endogenous compounds or NAT substrates and/or products influence NATl expression
(Butcher et aI., 2000a/b; Ward et aI., 1992). Yet others propose the possibility that NAT activity
and expression are influenced by non-genetic, or environmental factors (Butcher et aI., 1998).
While we don't completely understand NAT regulation outside of SNPs and genotype, it is clear
that in vivo N-acetyltransferase phenotype is influenced by genetic and environmental factors
independently of known NAT genotype (Rodrigues-Lima and Dupret, 2004).
Genetic influences on gene expression include cis-acting and trans-acting genetic factors
(Morley et aI., 2004). Unknown linked, or cis-acting, genetic factors could include unidentified
genetic polymorphisms in NATI and NAT2 promoters or other control regions that influence NAT
expression. Such SNPs could alter transcription initiation and/or efficiency, or affect mRNA
processing, folding, and/or stability. For example, a mutation in the promoter of the low-density
lipoprotein receptor gene identified in a familial hypercholesterolemia patient caused an 80%
reduction of the promoter activity (Mozas et aI., 2002). While cis-acting genetic factors account
for up to 35% of the variability in gene expression among individuals, trans-acting loci have an
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even greater influence on variability in gene expression throughout the genome (Pastinen and
Hudson, 2004). Unlinked, or trans-acting, genetic factors are variable among individuals due to
the uniqueness of their genetic backgrounds. These factors include polymorphic genes outside
the NAT J and NAT2 loci that influence their expression, such as transcription factors or other
expression control proteins. The function of trans-acting genes could vary among individuals as a
result of SNPs or other function-affecting factors that influence their expression and/or activity.
The expression of HMG-CoA reductase provides an example of this type of gene regulation.
HMG-CoA reductase expression in mouse liver is about 5-fold higher in C57BLl6 mice than
BALB/c mice. Cis-acting genetic factors affecting the structural gene were ruled out as a cause
for this tissue-specific variation of HMG-CoA reductase mRNA expression, and a trans-acting
locus that controls the gene's expression was found to be the determining factor (Hwa et aI.,
1992). Both cis-and trans-acting genetic factors should be seriously considered for their possible
role in regulating the expression of N-acetyltransferases, and NATl in particular.
In addition to genetic influences on NAT expression, environmental stimuli may
influence NAT expression.

Environmental influences may include occupation-related and/or

lifestyle-related factors such as cigarette smoke or exposure to industrial chemicals. Experiments
in cell culture have shown that NAT expression is influenced by external stimuli such as
curcumin, a spice (Chen et aI., 2003), the anticancer drug paclitaxel (Yang et aI, 2003), luteolin, a
compound found in many common edibles such as celery and peppermint (Su et aI., 2003), even
Vitamin C (Hung and Lu, 2001) and acetaminophen (Roth en et aI., 1998). These influences act
to induce or inhibit NAT mRNA expression and/or enzyme activity in the cell culture systems
tested.

Other cell culture experiments suggest that NAT substrates (p-aminobenzoic acid, p-

aminosalicylic acid, ethyl-p-aminobenzoate, and p-aminophenol) down-regulate NATI activity
by down-regulating NATl protein, while mRNA remained unchanged (Butcher et aI., 2000b). In
similar

studies,

hydroxylamine-PABA

irreversibly

inactivated

NAT 1 though

covalent

modification of the enzyme active site (Butcher et aI., 2000a). Inactivation of NATl enzymes by
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their substrates and other xenobiotics may also take place at the level of transcription VIa
xenobiotic-inducible regions on NATI and NAT2 promoters (Mitchell and Warshawsky, 2003).
Other studies suggest substrate-dependent post-translational inactivation via substrate-induced
conversion of the NAT 1 active site from a stable acetylated state to an unstable deacetylated state,
thereby leaving the active site cysteine unprotected and resulting in the ubiquitination and
subsequent degradation of the NATI enzyme (Butcher et aI., 2004a).

Oxidative stress and

cellular redox stress may also influence NAT 1 activity. Reactive oxygen species (ROS), such as
hydrogen peroxide, can inactivate NATI by reacting with its active site cysteine. This results in a
sulfenic acid form that is reversible by reducing agents such as reduced glutathione (Atmane et
aI., 2003).

Reactive nitrogen species (RNS), such as S-nitrosothiols, also inhibit the NAT!

enzyme by targeting and modifying the reactive cysteine at its active site, resulting in a mixed
disulfide, a reaction that is also reversible in the presence of reducing agents (Dairou et aI., 2003).
Pathophysiological processes such as inflammation produce the highly reactive RNS
peroxynitrite that reacts with the active site cysteine to form sulfonic and sulfinic acids which,
unlike hydrogen peroxide and S-nitrosothiols, irreversibly inactivates NAT 1 (Dairou et aI., 2004).
UVB irradiation is an oxidative process that induces inactivation of NAT 1 and NAT2 in human
lens epithelial cells, also a reversible reaction (Dairou et aI., 2005). Overall, these studies have
shown that NAT! activity and/or expression is/are influenced by non-genetic factors such as
pharmaceutical drugs, environmental chemicals, cellular oxidants, and even inflammation-related
chemicals. More investigations are needed into assess the importance of these environmental
variables on N-acetyltransferase expression in an animal model. Further characterization of these
influences may aid in resolving the NATl genotype/phenotype inconsistencies and clarify NATl
molecular epidemiology data (Rodrigues-Lima and Dupret, 2004).
Some potentially important questions regarding the influence of genotype and
environment on NAT expression may help shape future investigations NATl and NAT2 tissuespecific expression. Can environmental exposures or unknown cis- or trans-acting genetic factors
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overwhelm the influence of an individual's NAT] and/or NAT2 genotype? Are genetic factors
(cis- and/or trans-acting factors, and tissue-specific expression) the primary determinants of NATl
and NAT2 acetylator phenotype, or do environmental exposures also influence acetylator
phenotype? Do environmental exposures and trans-genetic factors influence the expression of
NATl and NAT2 equally, or is one locus more sensitive to certain regulatory influences than the

other locus? The answers to these questions are important for understanding how NAT-mediated
individual predisposition to certain cancers is modified in individuals by better understanding the
factors that influence interindividual expression of NATl and NAT2.
How NAT] and NAT2 are tissue-specific expressed, and the genetic and environmental
influences on that expression, are thus far unknown. The lack of basic information regarding
NAT promoters and other expression control regions has precluded the search for cis-acting
mutations outside the coding region until lately. Recent identification of human NATl promoters
(Husain et aI., 2004) and the promise of the same for NAT2 (Husain et aI., 2003) should speed the
discovery of functionally significant polymorphisms in expression control regions (cis-acting
genetic factors).

A great deal of work remains to be done if we are to understanding N-

acetyltransferase tissue-specific expression and the environment and trans-acting genetic
influences that modify that expression.
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CHAPTER II
NAT! EXPRESSION IN PRIMARY HUMAN HEPATOCYTES

Introduction

Cryopreserved human hepatocytes are an ideal system for analyzing genotype/phenotype
relationships. The advantages of primary cell culture, the ability to work with a single cell type
that has not been altered through an immortalization process (Li et aI., 1999; Sun et aI., 1993),
and the convenience of cryopreserved samples that are conveniently accessed at will, are
combined into one with cryopreserved hepatocytes. Since the liver is a key site for xenobiotic
metabolism, and both NAT! and NAT2 are expressed in liver (Windmill et aI., 2000), hepatocytes
are suitable for studying N-acetyltransferase expression.
Our lab obtained 76 cryopreserved human hepatocyte samples, representing as many individuals
(In vitro Technologies, Inc., Baltimore, MD, USA). These hepatocytes were genotyped for NAT!

and NAT2 by real-time RT -PCR using previously published methods (Doll and Hein, 2001; Doll
and Hein, 2002). The same samples were then tested for NAT 1 and NAT2 N-acetylation activity
using p-aminobenzoic acid (PABA) as the selective substrate for human NAT! (Doll et aI.,
1997), and sulfamethazine (SMZ) as the selective substrate for human NAT2 (Leff et aI., 1999b).
The results indicated that NAT! acetylator phenotype did not correlate with expected NAT!
phenotype, as deduced from NAT! genotype (Figure 3A). In fact, the acetylation rates varied
over 600-fold among NAT!*4/*4 individuals (n

= 38)

and over 350-fold among NAT! *4/*10

individuals (n = 24). The data for NAT!*IO/lO individuals were tighter, but the sample size was
much smaller (n

= 4).

The NAT2 data, on the other hand, demonstrated a clear correlation

between NAT2 acetylator phenotype and expected NAT2 phenotype, as deduced from NAT2
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Figure 3. Cryopreserved Hepatocyte NATl and NAT2 GenotypeIPhenotype Correlation
Cryopreserved hepatocytes were genotyped for NAT] and NAT2, then tested for NAT I and NAT2
N-acetylation activity using NATI-selective substrate p-aminobenzoic acid (PABA), and NAT2-selective
substrate sulfamethazine (SMZ). Activities were grouped according to genotype and plotted as shown
above.

(A) NA Tl *4 is the wild-type allele, and NA Tl *] 0 is a variant allele that demonstrates higher

activity than NATl*4 in vitro (Badawi et aI., 1995; Bell et aI., 1995b). NAT]*41*4 homozygotes and
NATl*41*JO heterozygotes demonstrate a wide range ofN-acetylation activities_ (B) NAT2*4 is the wild-

type rapid allele, and NAT2*5 and NAT2*6 alleles are slow alleles. Combining rapid NAT2*4 with a
NAT2*5 or NAT2*6 allele results in intermediate phenotype. Genotyping and enzyme activity assays were

performed by Mark Doll.
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genotype (Figure 3B).
This is not the first time this phenomenon has been observed for NAT]. Other studies
have documented a lack of correlation between NA T] genotype and phenotype in placenta (Smelt
et aI., 1998), breast (Williams et aI., 200 I), and whole blood (Payton and Sim, 1998). Possible
reasons for this discrepancy between NA Tl genotype and expected acetylator phenotype could
include the following: (I) the existence of unidentified cis-acting genetic factors, such as
polymorphisms in NATl expression control regions; (2) environmental influences on NAT]
expression; (3) variability in trans-acting genetic factors among individuals who have distinct
genetic backgrounds. These factors were discussed in Chapter I.
It is clear from Figure 3 that factors other than NAT] genotype influence NATI acetylator
phenotype in hepatocytes, as in the other tissue types mentioned above. The background data for
the individuals from whom the hepatocytes originated is not sufficiently detailed to draw
correlations between environmental exposures and NATl expression. Due to the complexity of
biological interactions with the environment, it is doubtful whether such correlations are possible
even with the most detailed background information. Since one cannot experimentally analyze
the hepatocytes to determine environmental influences on NATl phenotype, the focus must be
shifted to genetic influences.
As already mentioned, some have suggested that this problem might be solved following
more thorough characterization of NA Tl polymorphisms (Payton and Sim, 1998). If unknown 5'UTR SNPs influence NAT] expression, characterization of these SNPs may bridge the gap
between NAT] genotype and phenotype.

Since the entire NAT] gene is at least 12 kb long

(Husain et aI., 2004), sequencing this entire region in a large number of individuals to find
polymorphisms in this region is practically impossible.

Therefore, a different approach is

necessary.
While many SNPs may exist in the NA Tl 5' -UTR, polymorphisms of interest are those
that have functional consequences for NATl expression. Functional consequences of coding
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region SNPs can be detected as alterations of enzyme activity. Functional SNPs in the 5' -UTR
can only be detected at the level of mRNA transcription and possibly protein translation. The
fundamental strategy for the experiments described in this chapter is based on the former.
Experiments were designed based on competing hypotheses. The first hypothesis is that
the dramatic variation in human hepatocyte NATl PABA activity within each genotype is the
result primarily of cis-acting SNPs in the 5' -UTR of the NATl locus. If the data support this
hypothesis, functionally important mutations exist in the 5' -UTR, providing compelling evidence
to justify future investigations that analyze the NATl locus for unknown SNPs. The alternative
hypothesis is that dramatic variation in human hepatocyte NATI PABA activity is not caused
primarily by genetic differences among individuals at the NATl locus. If the data support the
alternative hypothesis, environmental or trans-acting genetic factors (genetic variability outside
the NATllocus) influence NATl expression, warranting further investigation into the influence of
these factors.
SNPs in the 5' -UTR could directly alter transcription activity by affecting interactions
between transcription factors and the NATl promoter, by altering exon splicing patterns, altering
mRNA structure, etc. Polymorphisms in the 5' -UTR could be as far away as 12 kb or more from
the NA Tl coding region. Due to genetic recombination by crossing over, these polymorphisms
could recombine independently of the NATl coding region. In this case, specific 5'-UTR SNPs
would not associate with specific NATl alleles, but would be distributed randomly among all
known NATl alleles.

For example, two individuals may have the same NATl allele, say

NATl*41*4, but have different polymorphisms in the 5'-UTR of the NATl gene, resulting in
drastically different acetylator phenotypes. The complexity of the interactions between 5' -UTR
polymorphisms and NA Tl alleles would depend on the number of 5' -UTR polymorphisms in the
population and how drastically they influenced activity (we are only interested in functionally
important polymorphisms). The experiments described in this chapter were designed based on
these ideas.
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The strategy implemented to test the competing hypotheses involves analysis of the
hepatocytes for functionally important polymorphisms by testing for differences in transcription.
Since NATl genotypes will harbor unknown 5' -UTR polymorphisms if the first hypothesis is
true, it is necessary to measure the expression level of NATl alleles independently to determine
whether the alleles are influenced by some unknown difference that causes them to express at
different levels. Significant allelic expression differences will be indicative of unknown functionaltering polymorphisms that result in different mRNA transcription rates.

Since the first

hypothesis requires very large mRNA expression differences in order to account for the very
large variability in enzyme activity, the allelic expression differences will not be subtle and
therefore identification should be straightforward.
The above strategy requires measurement of NATl alleles independently.

NATl

genotypes among the hepatocyte were mostly combinations NATl*4 and NATl*1O alleles, with a
large portion of these NA Tl *41* 10 heterozygotes.

Since differences cannot be measured in

homozygous individuals, the NATl *41*10 hepatocytes are ideal for this type of analysis. Since
the 5' -UTR polymorphisms are far enough away from the coding region to be recombined
independently of one another, it is reasonable to think that 5' -UTR polymorphisms will be spread
among all NATI alleles.

With NATl*4 as the reference allele, NATI*1O has polymorphisms

T\088A and C\095A in the 3'-UTR within the first poly-adenylation signal. These SNPs make

NA Tl *J0 alleles distinguishable from NA Tl *4 alleles by the sequence recognition techniques
described in the methods section.

Comparing NATl*1O and NATl*4 mRNA expression in

NATl*41*JO heterozygous hepatocytes will reveal whether polymorphisms in the 5'-UTR result
in different versions of the NA Tl *4 and NA Tl *10 alleles that have drastically different
expression to account for the lack of correlation between NATl genotype and phenotype in these
hepatocytes.
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Methods
Cryopreserved Hepatocytes
Seventy-six

cryopreserved

hepatocyte

samples

were

obtained

from

In

Vitro

Technologies, Inc. (Baltimore, MD) and stored in liquid nitrogen upon arrival. Due to limited
sample availability following other analyses on these hepatocytes, 17 of the 24 original
NATl *41* 10 heterozygote hepatocyte samples were available for analysis at the time of this

experiment. The NAT I enzymatic activities of these 17 hepatocytes varied over 350-fold and
therefore included samples with a representative range of enzyme activities.
Determination of Method Sensitivity
Prior to analyzing hepatocyte NATl*4 and NATl*1O expression by real-time RT-PCR, it
was necessary to test the method's ability to accurately detect differences in NATl*4 and
NATl*1O mRNA expression. Analysis of a sample with equal amounts of NATl*4 and NATl*lO

mRNA should give aBele ratio of 1.0. However, this value may deviate from 1.0 due to the
characteristic sensitivity of the real-time PCR method, instrumentation, and differences between
the NATl*4 and NATl*lO mRNA probes in their annealing and cleavage (by polymerase)
efficiencies. Therefore, standards were necessary to determine the range of values surrounding
1.0 that should be considered as indicative of a 1.0 aBele ratio. Anything outside of this range is
considered significantly different from 1.0, and is indicative of a real difference in expression
between the NA Tl *4 and NATl *10 aBeles. This type of analysis requires a standard guaranteed
to have equal amounts of NATl*4 and NATl*1O DNA sequence.

Genomic DNA is the ideal

standard since, by definition, genomic DNA from heterozygous individuals contains equal copies
of each aBele. In theory, NATl*41*1O heterozygous hepatocyte genomic DNA samples should
have a T~CT value of 1.0 for the ratio of NATl*4 to NATl*IO.
Genomic DNA from 8 different NATl*4INATl*lO heterozygous individuals was used as
template for real-time PCR analysis (Figure 4). The reaction mixture contained NATl-specific
TaqMan primers (forward, 5' -gaaacataaccacaaaccttttcaaa-3' ; reverse, 5' -aaatcaccaatttccaagat
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Figure 4. Real·Time PCR of NATl*4 and NATl*JO eDNA
The region of cDNA containing the single nucleotide polymorphisms (SNPs) is amplified using

gene-specific primers. Fluorogenic TaqMan probes complementary to the sequence being detected anneal
to the specific PCR products as they are created, allowing real·time detection of specific peR products.
TaqMan probes have a tluorogenic reporter dye on the 5' end and a quencher on the 3' end. The quencher
reduces the fluorescent signal of the reporter dye by fluorescence resonance energy transfer (FRET). After
the probe anneals to the specific target sequence, the 5' nuclease activity of AmpliTaq Gold polymerase
cleaves the probe and separates the quenchcr from the reporter dye, resulting in an increase in fluorescence
reading. The probe is cleaved as the polymerase extends the target sequence so that peR extension of the
target sequence is not interrupted.
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-aacca-3') (Applied Biosystems, Foster City, CA), FAM-Iabelled NATl*4-specific (5'atctttaaaagacatttattattatta-3') and VIC-labelled NATl *JO-specific (5' -catctttaaaatacattttttattatta-3 ')
fluorogenic TaqMan probes (Applied Biosystems), hepatocyte genomic DNA and TaqMan
Universal PCR Master Mix (Applied Biosystems), which contains AmpliTaq Gold polymerase.
Real-time PCR was performed using an ABI Prism 7700 sequence detection system from Applied
Biosystems. The reaction conditions were identical to the conditions used for genotyping the
hepatocyte samples. These conditions, in addition to the primer and probe design, were described
previously (Doll and Hein, 2002).
Allele-Specific Expression in Hepatocyte Samples
Cryopreserved hepatocytes were thawed on ice, then pelleted according to the
manufacturer's instructions, and homogenized using QIAshredder columns from Qiagen
(Valencia, CA). RNA was isolated using the RNeasy Kit from Qiagen, and then separated by
electrophoresis on a 1% agarose gel to test the RNA quality by observing the distinct 28S and
18S ribosomal RNA bands. RNA samples were then treated with DNase using the Turbo DNase
kit from Ambion (Austin, TX) and stored at -80°C. RNA was quantified by separating the RNA
by electrophoresis on a 1% agarose gel along with RNA standards in known amounts (200 ng,
400 ng, 800 ng). RNA concentration was determined by densitometric analysis based on the
standard curve.

RNA samples were reverse transcribed using SuperScript III First-Strand

Synthesis System for RT-PCR from Invitrogen (Carlsbad, CA). Control reverse transcription
reactions were also performed in the absence of reverse transcriptase as controls for DNA
contamination. All hepatocyte samples were analyzed for B-actin expression as a normalizing
control. Real-time PCR was performed on the hepatocyte cDNA samples, as described above for
the genomic DNA samples.
Standard Curve for Allele-Specific Measurements
A standard curve was designed for further analysis of the allelic expressIon data.
Whereas the real-time PCR primers used for amplifying NATl*4 and NATl*JO are identical, the

22

allele-specific probes are different for NA Tl *4 and NA Tl *10, and therefore can introduce
variability. The standard curve will take into account that variability and allow comparison of the
allele ratios minus the influence of the probe differences.
Hepatocyte

genomic

DNAs

from

NATl*41*4 homozygotes and NATl*lOI*1O

homozygotes were mixed in NATl*41*4:NATl*101*10 ratios of 100:0, 90:10, 70:30, 50:50,
30:70, 10:90, and 0: 100 to mimic situations in which the NA Tl *4 and NA T 1*10 alleles are
expressed in different ratios in the hepatocyte samples. These standards were designed to test the
ability of the method to detect differences in the expression of NATl*4 and NATl*1O alleles, as
well as to provide a standard curve with which to analyze allele-specific expression. These
mixtures were analyzed by real-time PCR and data were analyzed in the same way as the
genomic DNA controls.
Data Analyses
NAT 1 data were normalized to ~-actin by subtracting the ~-actin CT value from the
NA T1 CT value, give the LlCT value. The expression of NA Tl *4 and NAT 1*10 alleles in these
samples were analyzed as the ratio of NATl*4 mRNA to NATl*1O mRNA (NATl*4INATl*IO).
In the case of equal expression, the ratio equals 1.0; in the case of 2-fold higher NAT 1*4 than

NAT1*10, the ratio equals 2.0, etc. Therefore, the ratio of the NAT1*4 LlCT to the NAT1*10 LlCT
gives the MCT value.

Since CT values are inversely proportional to the amount of mRNA

expressed, it is necessary to normalize to a calibrator, resulting in 2- MC , (calculations derived
from Applied Biosystems' "User Bulletin #2: ABI Prism 7700 Sequence Detection System,"
2001). This value is mathematically equivalent to the ratio of individual NATl*4 to NATl*1O 2"'CT values. For real-time PCR of genomic DNA samples, the value 2-"'CT was calculated, since
genomic DNA was normalized to DNA concentration and not to an internal standard. This value
is equivalent to the ratio of NA Tl *4 to NAT 1 *10 2-CT values.
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Statistical Analyses
All assays were performed in triplicate, with each replicate performed on a different day,
and the standard error of the means (SEM) calculated for the set of triplicate experiments.
Analysis of variance (ANOV A) was used to determine differences among the allele expression
ratios for the 17 hepatocyte samples.
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Results & Discussion

Determination of Method Sensitivity
Analysis of heterozygous NA Tl *41* 10 hepatocyte genomic DNA by real-time peR
resulted in ratios ranging from approximately 0.5 to 1.5 (Figure 5). Therefore, when measuring

NATl*4 and NATl*1O expression in heterozygous hepatocytes, any allele ratio between 0.5 and
1.5 will not be considered as different than 1.0. Any ratio less than 0.5 or greater than 1.5 can be
considered different from 1.0, indicating that the alleles are expressed differently.
As is evident from the relatively wide range of ratios considered equal to 1.0 (0.5 - 1.5)
this method is not sensitive enough to detect small differences in allele expression. The method
is, however, sufficiently sensitive to detect large differences. Explaining the 350-fold range of
enzyme activities in the NA Tl *41* 10 hepatocytes in terms of cis-acting genetic polymorph isms
requires that the hepatocytes with the lowest activity possess a combination of very low
expressing NA Tl *4 and NA Tl *10 alleles. Likewise, the hepatocytes with the highest activity
possess a combination of higher expressing NATl *4 and NA Tl *10 alleles. If this theory is true,
the low expressing and high expressing alleles represented in these samples must have drastically
different expression rates.

Therefore, although a greater sensitivity might be achieved by

optimizing the method, the differences in NATl*4 and NATl*1O allele expression that we are
trying to detect are very large, eliminating the need for a more sensitive method.
Allele-Specific Expression in Hepatocyte Samples
The ratios of NA Tl *4 to NAT 1* 10 in 17 hepatocyte samples varied from approximately
0.5 to 3.3 (Figure 6). Five of these samples show significantly reduced NATl *10 expression
relative to NATl*4. The other 12 hepatocyte samples have allele expression ratios that fall within
the range of 0.5 - 1.5, and thus are not considered different than 1.0. Analysis of variance
(ANOV A) was performed on the data in Figure 6 showing that the data in this group are
significantly different (P =0.014).
Instead of a random distribution of high expressing and low expressing alleles, the data
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Figure 5. Quautitative Real-Time RT-PCR Sensitivity for NAT! Allele Expression Analysis
Heterozygous NATl*4INAT1*1O human hepatocyte genomic DNA samples were analyzed by
real-time peR. The experimentally determined ratios plotted above, have variability extending about 50%
above and below (dashed lines) the theoretically expected 1.0 ratio (solid line). Thus, due to the sensitivity
of the method, experimentally determined NATl *4 and NATl *10 allele expression ratios below 0.5 or
above 1.5 will be considered different from 1.0, while anything within this range falls within the limits of
detection for this method.
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NA T1 *4INA T1 *10 Allele Expression Ratio

Figure 6. Relative NAT1 Allele Expression in NATl*41* 10 Human Hepatocytes
Hepatocyte cDNA samples reverse transcribed from hepatocyte RNA were analyzed for NA Tl *4
and NATl*1O allele-specific expression by real-time peR. The NATl*4INATl*10 allele expression ratios
are displayed above. The solid line corresponds to a theoretical NATl *4INATl *10 expression ratio of 1.0.
The region between the two dotted lines, which lie above and below the solid line, represent the range of
expression ratios determined to not be different from 1.0 by this method (Figure 5). Several samples
demonstrate significant variation from 1.0, indicating unequal expression of the NATl*4 and NATl*1O
alleles.
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suggest a general trend of higher NA Tl *4 expression than NA Tl *] 0 expression. It is unclear at
this point, however, whether this trend is real or an artifact of characteristic differences between
the probes used to detect NAT] *4 and NA Tl *10 sequences. It could be that, compared to the
NAT] *] 0 probe, the NAT] *4 probe anneals to its target more readily and/or is cleaved more

readily by the polymerase. On the other hand, the NAT] *4 probe could lack complete specificity
for NATl*4, and anneal to NAT] *10 some of the time, thereby artificially boosting the NATl*4
signal. These factors were tested using a standard curve, as described in the next section.
The greatest difference between NA Tl *4 and NA Tl *10 expression observed m the
hepatocytes is approximately 3-fold. Therefore, there is no evidence to justify a conclusion that
enzyme activity differences in heterozygotes (350-fold) are solely caused by forms of NATl *4
and/or NATl *10 alleles that express differently.

However, the evidence of slight allelic

expression differences (- 3-fold), possibly caused by 5' -UTR polymorphisms, does not rule out
the possibility that different forms of known NAT] alleles exist or at least contribute to the lack of
correlation between NAT] genotype and phenotype in hepatocytes.
The question then remains: what can account for the inability of NATl genotype to
predict NATl phenotype? Instead of searching for polymorphisms in the 5' -UTR to explain the
discrepancy, the strategy described here directly tested the critical question of whether differential
mRNA expression can account for NATl phenotype. Since this study reveals that differential
mRNA expression cannot, in fact, account for NA T1 phenotype, the expectation that identifying
and characterizing 5' -UTR polymorphisms will clear up the problem can be set aside. The list of
explanations for NAT] phenotype has now been narrowed down to the influences of
environmental factors and/or trans-acting genetic factors on NATl mRNA and/or protein
expression.
Total NATl mRNA expression can be calculated by adding the quantitative expression
values for both NATl *4 and NATl *10 alleles. No correlation can be observed between total
NATI mRNA and NAT! enzymatic activity levels (Figure 7). This further supports the idea that
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Figure 7. Hepatocyte NAT! Activity and NAT1 mRNA Expression
The X-axis of each graph is labeled with hepatocyte sample identification codes. (A) Hepatocyte
NAT I enzymatic activities were measured using the NATI-selective substrate p-aminobenzoic acid
(PABA).

(B) Total NAT! mRNA expression was determined by calculating the sum of quantitative

NATl*4 and NATl*JO mRNA expression measurements. Comparison of NAT I enzyme activity and NAT1
mRNA in order of increasing enzyme activity reveals the lack of correlation between the two. In fact, the
sample with the lowest enzyme activity has one of the highest levels of NAT] mRNA expression, while the
sample with the highest enzyme activity has a relatively low NAT] mRNA expression.
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factors external to the NAT I locus, either genetic or environmental, are influencing NAT I
acetylator phenotype post-transcriptionally.

Possible mechanisms for such influences were

mentioned in the Chapter I, and therefore will not be discussed here.
One concern is that the relatively low stability of the NATI enzyme (Dupret et aI., 1994),
might take some responsibility for the difficulty in correlating NATI genotype to acetylator
phenotype.

However, there is no reason to believe that In Vitro Techologies somehow

mishandled the samples.

It is more likely that In Vitro Technologies has a great deal of

experience with these samples, and that they were prepared and handled consistently. The same
reasoning applies to their handling in our lab.

The very strong NAT2 genotype/phenotype

correlations in these same samples provide evidence for this. It is also important to note that the
lack of correlation between NA T I genotype and phenotype are not novel, but have been observed
and reported by others in this field as well (Payton and Sim, 1998; Smelt et aI., 1998; Williams et
aI., 2001), as discussed in Chapter I.
Standard Curve for Allele-Specific Measurements
Creating a standard curve and applying the hepatocyte samples to that curve revealed
information that might otherwise have gone unrealized. The standard curve clarified whether the
general trend of higher NAT I *4 than NAT I *I 0 expression in the hepatocytes is real or an artifact
of probe characteristics. Data from real-time PCR of NA Tl *4/*4 and NA Tl *10/* I 0 genomic
DNA mixtures were analyzed the same way as the allele-specific expression analyses in the
previous section. NA Tl *4/NA Tl *I 0 ratios were calculated (this time as

T<lC

T

values, since no

internal standard is applied) and plotted (Figure 8A). A standard curve was then created by
fitting a third order polynomial to these points (R 2

= 0.98),

giving an equation with which the

hepatocyte allelic expression data could be fitted to the curve (Figure 8B). This curve takes into
account the differences between the two probes used to recognize NA Tl *4 and NA Tl *I 0
sequences. The hepatocyte allele expression data were fitted to the curve by substituting the
L\L\CT values (Figure 6) for the "y" variable in the third order polynomial equation and solving
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Figure 8. Creation of a Standard Curve with NATl*41*4 & NATl*lOI*lO Genomic DNA Mixtures
Hepatocyte NATl*41*4 and NATl*lOl*lO genomic DNAs were mixed in various ratios to mimic
possible expression ratios of NAT] *4 and NATl *10 and analyzed by real-time PCR. (A) The

~CT

values

were plotted instead of the T~CT values, since the ~CT curve gave a polynomial equation that is more
convenient to use, and graphically easier to read and understand. (B) The

~CT

values were then fitted to a

third-order polynomial curve (equation shown on graph) with very close fit (R2 = 0.98). This curve will be
the standard curve for analysis of hepatocyte allele expression data relative to genomic DNA standards, and
the third order polynomial equation will be used to fit these data to the curve.
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for the "x" variable using the equation solver function of a Texas Instruments TI-86 calculator,
which equals the value corresponding to the correct NAT 1 *4:NA Tl *10 mixture. These new data
were then plotted on the standard curve (Figure 9) along with the genomic DNA samples from
Figure 5.
The analysis revealed that the trend of greater NA Tl *4 expression than NAT1 *10
expression is real and not an artifact of the probe differences. When plotted on this standard
curve using the third order polynomial equation, the genomic DNA samples, which should
theoretically come to an allele ratio of 1.0, had a mean NATl*4/NATl*lO ratio of approximately
l.l, or 53% NATl*4 and 48% NATl*1O. This suggests that the NATl*4 and NATl*1O probes act

differently in this real-time peR method. The hepatocyte allele expression data gave a mean
NATl*4/NATl*1O ratio of approximately 1.8, or 64/38; this means that 64% of the NAT I mRNA

was NA Tl *4 and only 38% was NA Tl *10. Mean allele ratios of the hepatocyte samples and the
heterozygous genomic DNA samples are significantly different according to at-test (P =0.0050).
The difference observed between the NATl*4 and NATl*lO alleles is not unusual in that
variations in allelic expression are common in the human genome (Shuen Lo et aI., 2003; Yan et
aI., 2002).

On the other hand, an observation of lower NATl*1O mRNA expression than

reference NATl*4 mRNA expression is unusual in light of reports that NATl*1O is a rapid allele
with reference to NATl*4 (Badawi et aI., 1995; Bell et aI., 1995b). Since NATl*1O is different
from NA Tl *4 only outside of the coding region, these NA Tl alleles code for the exact same
enzyme. Thus, the difference must be transcriptional or translational, and not related to enzyme
function. These data are apparently inconsistent with reports that bestow rapid allele status on
NATl*1O relative to NATl*4, but consistent with enzyme activity data from the cryopreserved

hepatocytes (Figure 3).
It is, however, unclear from our analysis whether the general trend of low NATl*1O
mRNA expression compared to NA Tl *4 is a genuine case of allele-specific expression. It is
possible that one of the 3' -UTR SNPs that defines NAT 1 *10 influences the detection of a certain
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Figure 9. Standard Curve Analysis of Hepatocyte NATl Allelic Expression
Hepatocyte eDNA

~~CT

values, NAT1*41*10 genomic DNA

NA T1 *101*10 homozygote genomic DNA

~CT

~CT

values, and NAT1*41*4 and

values (controls) were all fitted to the standard curve using

the third-order polynomial equation that describes the curve (displ ayed above). When the value for "y" is
inserted into the equation, solving for "x" gives a value corresponding to the NAT1 *4: NATI *IO mixture
ratio.

The mean allele ratio for NAT1 *41*10 genomic DNA standards (blue triangle) gives an

NA T1 *4:NATI *10 allele ratio of 53:47. The mean allele ratio for hepatocyte eDNA samples (red triangle)
gives a NATI *4:NAT1 *10 allele ratio of 64/36. Error bars on either side of these means indicate that the
standard error of the means (SEM) for these two means do not overlap. A t-test reveals the means are
significantl y different (P = 0.(050).
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percentage of NA Tl *10 transcripts by altering the poly-adenylation signal usage. If the first polyadenylation signal following the human NATl stop codon were utilized during translation, NATl
real-time PCR primers would be unable to amplify the necessary segment of that transcript, since
the primers anneal to sequences on either side of the signal. The T

1088

A SNP in NA Tl *10 DNA

sequence changes the thymine to an adenine in the first AATAAA poly-adenylation signal
following the stop codon. Such a change can have obvious deleterious effects on the use of this
signal (Sheets et aI., 1990). However, this SNP creates yet another stop codon, where the AAT
on the 5' end of the original signal become the three 3' adenine nucleotides on a new AATAAA
signal.
Instead of increased usage of this new poly-adenylation signal, which would decrease
detection

of

NA Tl *10 transcripts

and

give

reason

to

question

the

allele-specific

NA Tl *1O/NA Tl *4 expression data, it is expected that the usage of this new signal would decrease
instead of increase, or at least remain the same. Although the SNP creates a new signal only 3
nucleotides 5' of the original signal, the optimal distance between the poly-A signal and the site
where cleavage and poly-adenylation occur has been altered. Data suggest that there is a spatial
requirement for the distance between the poly-A signal and the actual site of cleavage/polyadenylation. Unless this requirement is met, efficient mRNA production may be compromised
(Nevins, 1983). On the other hand, analyses of mRNA structure using the "Fold" program (Zuker
and Stiegler, 1981) and "Squiggles" program (Osterburg and Sommer, 1981) suggest that the

NATl*1O polymorphisms do not alter the mRNA secondary structure (de Leon et aI., 2000), and
it is therefore believed that the altered poly-A site is well-tolerated.
Regardless of whether the TlO88 A SNP in the NA Tl *10 allele creates a less functional
poly-adenylation signal than the original NATl *4 allele or creates no change at all, there is no
reason to believe that the T

lO88

A SNP creates a more functional poly-A signal, resulting in a

fraction of NAT 1 *10 transcripts that could not be detected by the real-time PCR method described
above. The discrepancy still exists, however, between the reduced NAT 1 *10 mRNA expression
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described in this chapter and the designation of NATJ*JO as a rapid acetylator NATl allele by
others. Further analyses may determine that the paradox is explained by translational differences
due to 5'-UTR SNPs associated with the NATl*/o allele specifically. Such analyses are beyond
the scope of this study and will not be pursued.
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Conclusions
Quantitive real-time RT-PCR was used to detect allele-specific expression differences
with moderate sensitivity. Sequence detection using gene-specific primers and allele-specific
probes provides the necessary specificity.

With some optimization, this method could be

improved to allow for even greater sensitivity than was required for these experiments.
Analysis of NAT1*4 and NATl*1O mRNA expression in 17 NATl*41*1O cryopreserved
human hepatocytes by quantitative real-time RT-PCR provides evidence for cis-acting genetic
factors that can cause up to 3-fold difference in mRNA expression.

While these cis-acting

genetic factors may contribute to the observed discrepancy between NA Tl genotype and
phenotype in primary hepatocytes, differences in allele expression alone are not responsible for
the 350-fold difference in NAT! enzymatic activity in the hepatocytes examined. Fitting the realtime PCR data to a standard curve reveals possible allele-specific expression of these NA Tl
alleles; NA Tl *10 mRNA expression is significantly lower than NAT 1 *4 mRNA expression in the

NA Tl *41* 10 heterozygotes. This difference in expression appears to be real, and not an artifact
ofthe method, though more should be done to understand the NA Tl *10 allele.
These data point to the conclusion that unknown cis-acting genetic factors, such as NAT 1
polymorphisms in the 5' -UTR, do not account for the general discrepancy between NATl
genotype and phenotype in hepatocytes. They also, therefore, provide indirect evidence for the
influence of environmental factors and/or trans-acting genetic factors on NATl phenotype.
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Future Experiments
To test for a correlation between NATI enzyme activity and NAT] protein level, a
Western blot for should be performed on cytosols from the 17 hepatocyte samples analyzed in
this study. This experiment will complete the hepatocyte NAT] story and give an indication of
the role of translational and/or post-translational regulation on NAT! expression in hepatocytes.
Due to the lack of remaining sample from the 17 individuals represented in this study, more
hepatocytes from the same individuals will be ordered from In Vitro Technologies.
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CHAPTER III
A RODENT MODEL FOR STUDYING N-ACETYLTRANSFERASE TISSUE-SPECIFIC
EXPRESSION

Further investigation into NATl and NAT2 tissue-specific expression will require a model
that accommodates analysis of tissue mRNA and protein expression, and analysis of both genetic
and environmental influences on their expression. Every experimental model has characteristic
advantages and disadvantages that should be evaluated based on the purpose of the study and the
quality of information that the model can provide for completing the aims of the study.
Since the importance of studying N-acetyltransferases lies primarily in its human
application, directly studying human tissues and human NAT genes is preferred. However, the
disadvantages of analyzing human tissues for this type of study far outweigh the benefit. Human
tissues can be obtained from a variety of sources, including the National Cancer Institute's
Cooperative Human Tissue Network and the Armed Forces Institute of Pathology National
Pathology Repository (Eiseman and Haga, 1999). However, the availability of each sample is
limited and the quantity and quality is variable and unpredictable. In addition, there are no
guarantees that the tissue section obtained is representative of the whole tissue, which is
important when comparing tissue-specific expression of multiple individuals. The quality of the
tissues is questionable since the method and time of tissue collection are often unknown and
highly variable.

Due to possible deleterious effects of mishandling on mRNA and protein

preservation, tissue quality and the consistency of tissue handling and processing are very
important when analyzing mRNA and protein expression. Perhaps more importantly, the natural
variability associated with interindividual human environmental exposures, and the distinct
genetic backgrounds among humans make human tissues an inappropriate system for studying the
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tissue-specific expression of genes whose expression may be influenced by trans-genetic and
environmental variables.
Animal models are the ideal system for studying tissue-specific expression in the absence
of unpredictable environmental exposures and genetic variability, and they also provide the most
direct and effective means of studying the influence of genetic variability and environmental
exposures on gene expression. Mores specifically, the rat model is often used as a system for
better understanding human gene expression; many gene expression studies in rat are used to
extrapolate meaningful conclusions about what might also be true for expression of analogous
human genes (Ariel et aI., 2004; Sigfrid et aI., 2004; Van Tuyl et aI., 2003).
As is the case with human tissues, use of rat tissues as a model for NATl and NAT2
expression has advantages and disadvantages. Advantages include the near unlimited availability
of any tissue of interest, and the freedom to analyze a specific and consistently chosen section of
tissue (or even the whole tissue) to ensure that expression measurements are consistent and
representative of the many cell types that make up a tissue. The quality of the tissues that can be
obtained from an animal model is ideal, since the procedures used for tissue harvesting can be
kept consistent from sample to sample, and the tissues can be preserved immediately following
harvest. Other advantages include the controlled environment of animal storage facilities and the
genetic consistency that can come from using inbred rat strains. These advantages must be
weighed against a disadvantage, common to any animal model, which is the questionable
relevance of rat Nats to human NATs.
The relevance of in vivo rat studies to human NATl and NAT2 could be addressed by
comparing nucleotide and protein sequences. Both rat and human N-acetyltransferases have a
single intronless 870 base pair coding region (Matas et al. 1997).

Rat and human N-

acetyltransferase genes and enzymes have high sequence identities, as much as 80% amino acid
sequence identity and 84% nucleotide sequence identity. More importantly, the catalytic triad,
Cys68-His 107 -Asp 122 (Sinclair et aI., 2000), is identical in rats and humans, thus implying the
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same catalytic function.

The three amino acids that play an important role in determining

substrate selectivity in human NATI and NAT2 can be compared to rat protein sequences. In
fact, human NATI and rat Nat2 have the same three amino acids at these sites, Phe 125-Argl 27Tyr129, suggesting that they have similar substrate selectivities. Human NAT2 and rat Natl, on
the other hand, while they share only one identical amino acid, have similarities in their
sequences with SerI25-SerI27-Ser129 for human NAT2 and Tyr125-SerI27-TyrI29 for rat Nat\.
This would suggest that rat Nat I and human NAT2 have similar substrate selectivities. Overall,
gene and protein sequence comparisons suggest that rat and human N-acetyltransferases share the
same biological functions in vivo.
Rats could also provide a good in vivo model for rapid and slow N-acetyltransferases
alleles.

While most rats are rapid acetylators (Nat2*20 allele), two rat strains have been

identified as slow acetylators.

Slow Nat2 alleles have been identified in rat strains WKY

(Nat2*21A) and NSD (Nat2*21B). The Nat2*21A slow allele has the four transitions G 361 A,

G399A, G796 A, and G 522 A, while the NAT2 *21 B slow allele has the four transitions G361 A, G399A,
G796 A, and C672T (Hein et aI., 1991 a,b; Juberg et aI., 1991). The mechanism by which these
SNPs confer slow acetylator status is unknown and should be studied further.
Although sequence similarities are compelling, a correlation between rat and human Nacetyltransferases must be experimentally determined.

This might be accomplished by

comparing the catalytic properties, substrate selectivity, and structural stability of the rat and
human N-acetyltransferase enzymes, thereby validating the rat model as a legitimate model for
studying N-acetyltransferases in vivo.

Before this could be done, however, the suspected

existence of a third functional rat N-acetyltransferase had to be identified (Chapter IV).
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CHAPTER IV
IDENTIFICATION, CLONING, AND SEQUENCING OF A NOVEL RAT
N-ACETYLTRANSFERASE (NATJ)

Introduction

N-acetyItransferases are expressed in a wide range of animal species.

Certain

characteristics are conserved across species, including the Cys-His-Asp cysteine protease-like
catalytic triad and the 870 base pair intronless coding region. Other aspects, however, are highly
variable, such as the exact coding region nucleotide sequence and even the number of NAT
isoforms encoded for within the organism's genome. The human genome contains two functional
N-acetyltransferase genes, NAT] and NAT2, and also an inactive pseudo-gene called NATP (Blum
et aI., 1990). NATP resembles a human N-acetyItransferase in its nucleotide sequence, and might
have been an active NAT gene at one time. Other animals, however, have more or fewer Nacetyltransferase isoforms; mice have three (Kelly and Sim, 1994), cats have only one (Trepanier
et aI., 1998), and dogs have none (Trepanier et aI., 1997).
The discovery of murine Nat3 hinted at the existence of a similar third Nat gene in rats.
This suspicion was confirmed with the appearance of a GenBank entry for "rattus norvegicus
similar to mouse Nat3" (XM_224762).

This potential rat Nat3 sequence was predicted by

automated computational analysis from an annotated genomic sequence (NW_047470) using a
gene prediction method called GNOMON (National Center for Biotechnology Information). The
sequence comes from rat strain BN/SsNHsdlMCW, which is a Brown Norway substrain from
Harlan Sprague Dawley, Inc., and the Medical College of Wisconsin.
The validity of the rat as a model for N-acetyltransferase activity and expression could be
affected by the existence of a third rat N-acetyltransferase gene. If rat Nat3 contributes in large
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part to acetylator phenotype in rat tissues, the lack of an equivalent human gene could render the
rat less valid as a model. On the other hand, the third N-acetyltransferase gene could have similar
properties to the third mouse N-acetyltransferase gene.

Mouse Nat3 enzyme has very low

activity relative to mouse Natl and Nat2 (Estrada-Rodgers et aI., 1998; Fretland et aI., 1997).
Therefore, the importance of rat Nat3, which is very similar to mouse Nat3 in nucleotide and
amino acid sequence, is questionable. This chapter describes the cloning and sequencing of rat
N-acetyltransferase 3.
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Methods

Cloning of the Rat Nat3 Gene
The rat Nat3 coding region was amplified from Fisher 344, Sprague Dawley, and Wistar
Kyoto genomic DNA by duplicate independent PCR reactions using Taq polymerase (Perkin
Elmer Corp., Norwalk, CT, USA).

Gene-specific primers were designed using GenBank

sequence "rattus norvegicus similar to mouse Nat3" (XM_224762). The forward PCR primer has
sequence 5' -gtagcaIT£gggatggacattgaagcgtactt-3'
(underlined)

to

facilitate

cloning.

The

and contains an Xmaf restriction

reverse

PCR

primer

has

sequence

site
5'-

atgcgactgcagctaaatagtaaaaagccaatt-3' and contains a Pstf restriction site (underlined) to facilitate
PCR-amplified Nat3 was then ligated into pcDNA3.1 TA cloning vector and

cloning.

transformed into TOPIO competent E.coli using a TA Cloning Kit (Invitrogen). Successfully
transformed E.coli colonies were selected for by ampicillin resistance, and then a single colony
was grown in 200 ml of liquid broth (l00 flg/ml amplicillin) overnight at 37°C. Plasmid DNA
was isolated from the E.coli using the Qiagen Plasmid Midi Kit (Qiagen, Inc., Valencia, CA,
USA).
Sequencing of the Rat Nat3 Gene
The Nat3 plasmid insert was completely sequenced USIng commercially available
plasmid-specific primers 5' -taatacgactcactataggg-3' (T7 - forward), and 5' -tagaaggcacagtcgagg3'

(BGH

reverse),

and

newly

designed

gene-specific

forward

primers

(5'-

tgcatactaccagaaatctccaa-3', 5' -tgccatcttccacttgacagaa-3', 5' -tcttctttactgggctctga-3'), and genespecific reverse primers (5' -cagtaaagaagatgattgacttgaa-3', 5' -gtcaattccagaggctcccacat-3', 5' gataagaatggtgcctactaaa-3'), to ensure complete coverage of both top and bottom strands of the
sequence.

Sequencing reactions were performed using BigDye Terminator v1.1 Cycle

Sequencing Kit (Applied Biosystems, Foster City, CA, USA), and the sequencing analysis
performed by an ABI 310 Genetic Analyzer (Applied Biosystems).

Sequencing data were

analyzed using SeqManII v.5.03 from DNASTAR Inc. (Madison, WI, USA).
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Results & Discussion

Rat Nat3 sequencing of both top and bottom strands was successfully accomplished for
rat strains Fisher 344 (F344), Wi star Kyoto (WKY), and Sprague Dawley (SPRD) (Figure 10).
No SNPs were found among all three strains sequenced. The sequence did, however, differ from
the GenBank predicted sequence (XM_224762) by a single nucleotide. The predicted sequence
from the BN strain contains a guanine at position 358, while the F344, WKY, and SPRD have an
adenine at this position. The difference manifests itself in an amino acid coding change from
valine (G at 358) to isoleucine (A at 358). Nucleotide sequence comparison of all known human,
mouse, and rat N-acetyltransferase loci reveals that nucleotide position 358 is an adenine in all of
them. Since the predicted Brown Norway Nat3 sequence resulted from a large-scale sequencing
project instead of direct sequencing of the gene, it is unclear whether the difference between the
predicted BN sequence and the F344, WKY, and SPRD sequences is indicative of a single
nucleotide polymorphism or a sequencing error from the large-scale sequencing project.
As is true with all known N-acetyltransferases, the Cys-His-Asp catalytic triad is present
in rat Nat3, suggesting that it has true N-acetyltransferase catalytic activity. The three nucleotides
determined to playa role in substrate selectivity (Goodfellow et aI., 2000) in Nat3 are unique
among the human NATs and rat Nats, but identical to those found in the published mouse Nat3
sequence (Figure 11). This suggests that Nat3 will have a unique substrate selectivity among rat
Nats, but similar, if not identical, to mouse Nat3. Rat Nat3 nucleotide sequence is 76% identical
to rat NatJ and 78% identical to rat Nat2; rat Nat3 amino acid sequence is 71 % identical to rat
Natl and 72% identical to rat Nat2 (Figure 12). The highest amino acid and nucleotide sequence
identity to rat Nat3 is with mouse Nat3, at 88.3% and 91.1 %, respectively.
Analysis of chromosomal gene location using NCBI Map Viewer (Wheeler et aI., 2005)
and BLAT from UCSC Genome Bioinformatics (Kent WJ, 2002) reveals that all three rat Nats
are located within about 75 kb on rat chromosome 16. The order of the rat genes 5' to 3' is NatJ-

Nat2-Nat3, with about 10 kb between Natl and Nat2, and about 60 kb between Nat2 and Nat3.
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Figure 10. Rat Nat3 Nucleotide and Deduced Amino Acid Sequences
The nucleotide sequence for rattus norvegicus N-acetyltransferase 3 (Nat3) was determined by
automated DNA sequencing for strains Fisher 344, Wistar Kyoto, and Sprague Dawley. Deduced amino
acid sequence is shown also. The locations of the catalytic triad (single underline), the sites influential in
substrate specificity (double underline), and the one nucleotide/protein sequence discrepancy with
reference XM_224762 at nucleotide 358 (bold) are marked as indicated. This sequence was published in
GenBank for strains Sprague Dawley (A Y253757), Wistar Kyoto (A Y253758), and Fischer 344
(A Y253759).
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125 127 129

A

Human NAT 1 -DAGFGRSYQMWRat Nat2 -DAGFGRSYQMWMouse Nat2 -DAGFGRSYQMW-

B

Human NAT 2 -DAGSGSSSQMWRat Natl -DSAYGSSYQMWMouse Natl -DSAYGGSYQMW-

C

Rat Nat3 -DSAFPFSCQMWMouse Nat3 -DSAFPFSCQLW-

Figure 11. Amino Acids 125, 127, 129 Influence N-acetyltransferase Substrate Selectivity
Human NATl, rat Nat2 and mouse Nat2 share the same amino acids at sites 125, 127, and 129
(phenylalanine-arginine-tyrosine) suggesting that these enzymes have very similar substrate selectivities.
Human NAT2, rat Natl, and mouse Natl do not have identical amino acids at these sites; however, the
amino acids are somewhat similar, suggesting that substrate selectivities may be similar. Rat and mouse
Nat3 enzymes have identical amino acids at these sites (phenylalanine, phenylalanine, cysteine), suggesting
that the substrate selectivities will be identical.
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Figure 12. Human, Mouse, and Rat N-acetyltransferase Sequence Homologies
Both nucleotide (bottom left half) and am ino acid (top right half) sequence compari sons for
human , mouse. and rat N-acetyltransferases were determined using EMBOSS pairwise alignment
algorithms (Rice et aI., 2(00).

The highest sequence identities, for both nucleotide and amino ac id

sequence comparisons, are between rat and mouse Nats. The lowest nucleotide sequence identitites. for

both nucleotide and ami no acid sequence comparisons, are between Nat3 (rat and mouse) and the human
NATs.
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This order is the same for the mouse Nats on mouse chromosome 8, and also for human NAT!
and NAT2 on human chromosome 8. Rat Nat3 sequences for strains SPRD, F344, and WKY
were published in Genbank with accession numbers AY253757, AY253758, and AY253757,
respectively.
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CHAPTER Y
CHARACTERIZATION OF RAT N-ACETYLTRANSFERASES NATl*13, NAT2*20,
NAT2*21A, NAT2*21B, AND NAT3 BY CLONING AND RECOMBINANT EXPRESSION IN

ESCHERICHIA COLI

Introduction
The usefulness of the rat as a model for N-acetyltransferase studies depends on a good
correlation between rat and human N-acetyltransferases. Although the comparison of rat and
human N-acetyltransferase nucleotide and protein sequences suggests that such a correlation
exists, it must be confirmed experimentally. Rat Natl*13, Nat2*20, Nat2*21A, and Nat2*21B
have been characterized already to some extent (Hein et aI., 1997; Doll and Hein, 1995).
Previous studies determined that rat Natl and Nat2 have unique substrate selectivities
that suggest rat Natl is similar to human NAT2, and rat Nat2 similar to human NATl, thereby
suggesting a correlation between the rat Nat and human NAT enzymes. This inverse correlation
is further supported by intrinsic stability data, which revealed that the trend for rats is Natl >
Nat2, and the stability of human NATs has the trend NAT2 > NATl (Gray et aI., 1996).
However, since rat Nat3 was recently discovered, the characterization of the rat Nats is
incomplete.
The slow acetylator rat Nat2*21A and Nat2*21B alleles have four SNPs each. Two of
the SNPs in each slow allele are silent (G 399A and G

522

A in Nat2*21A; G 399A and C

672

T in

Nat2*21B), while the other two cause y121I (G 361 A) and y266 I (G796A) amino acid changes in both
slow alleles. Thus, while Nat2 *21 A and Nat2 *21 B differ in their nucleotide sequence at two
positions (522 and 672), they code for identical proteins. Kinetic data suggest that Nat2*20 is
rapid while Nat2 *21 A and Nat2 *21 B are slow, but also that there is a significant difference

49

between the expression of Nat2*21A and Nat2*21B (Doll and Hein, 1995). The validity of the
last finding is in question, however, since a difference between Nat2*21A and Nat2*21B would
require that the silent nucleotide differences between the two alleles somehow influence mRNA
expression, mRNA stability, and/or translational efficiency due to alterations in mRNA structure.
Further experiments are needed to delineate the mechanism of the rat Nat2 slow acetylator
polymorphic alleles, and the difference between the two Nat2 slow alleles needs to be confirmed
and characterized.
To test the correlation between human NATs and rat Nats, understand the extent of their
similarities, and thereby validate the rat as an in vivo model for this research and for future in vivo
rat Nat research, the rat N-acetyltransferases were further characterized, as described in this
chapter. For the first time all three rat Nat loci, including all three Nat2 enzymes, have been
characterized in the same expression system, and at the same time.

Rat N-acetyltransferase

isozymes were characterized for catalytic activity, substrate selectivity, thermostability, and
immunoreactive detection by various polyclonal antisera.

In addition, experiments were

performed to delineate the Nat2 slow acetylator mechanism and the relationship between the two
slow Nat2 enzymes. Substrates tested include p-aminobenzoic acid (PABA), 4,4-methylenebis(2chloroaniline) (MOCA), N-(p-aminobenzoyl) glutamate (pABG), 4,4-methylenedianiline (MDA),
4-aminobiphenyl (ABP), 2-aminofluorene (AF), and sulfamethazine (SMZ). PABA is a known
human NAT1- and murine Nat2-selective substrate, while SMZ is a known human NAT2- and
murine Natl-selective substrate (Estrada-Rodgers et ai., 1998; Grant et ai., 1991). The first and
only suspected endogenous N-acetyltransferase substrate, pABG, is a folic acid catabolite and a
human NAT 1- and murine Nat2-specific substrate (Estrada-Rodgers et ai., 1998; Minchin, 1995).
4-Aminobiphenyl is a bladder carcinogen found in cigarette smoke (Schulte et ai., 1988; Vineis,
1994); this carcinogen is acetylated by both human NATI and NAT2 and mouse Natl and Nat2,
but with higher affinity for human NAT2 (Hein et aI., 1993) and for mouse Nat2 (Fretland et aI.,
1997b). 2-Aminofluorene is a carcinogen that has higher affinity for mouse Nat2 than Nat 1
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(Fretland et ai., 1997b).

MDA and MOCA are suspected human carcinogens (National

Toxicology Program, 2002a/b) whose metabolism may be influenced by N-acetylation.
Characterization of the rat Nats will lay a basic foundation for understanding rat Nacetyltransferases, and facilitate evaluation of the probable importance of Nat3, since nothing is
known about its activity and it has no human analog. Since mouse Nat3 has very low activity
relative to mouse Nat I and Nat2 (Estrada-Rodgers et ai., 1998; Fretland et ai., 1997), the
importance of rat Nat3, which is very similar to mouse Nat3 in nucleotide and amino acid
sequence, is questionable. The information gained from these experiments is preliminary data to
investigations using the rat as an in vivo model for N-acetyltransferase studies.
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Methods

Cloning Rat Nat2 and Nat3
Rat Nat2 alleles were cloned from PCR products into a bacterial expression vector,
whereas rat Nat3 was sub-cloned from the Nat3-pcDNA3.1 vector described in chapter IV into a
bacterial expression vector. Rat Nat2*20, Nat2*2]A, and Nat2*2]B were amplified from the
genomic DNA of rat strains F344, WKY, and NSD, respectively, using high fidelity Phusion
polymerase (Finnzymes, Finland) and Nat2-specific PCR primers. The Nat2 forward primer has
the sequence 5' -tctgaattcatggacattgaagcatactttgaaagaattggttat-3', with an EcoR] restriction site
(underlined) designed into the 5' -end to facilitate cloning (Doll and Hein, 1995). The Nat2
reverse primer was newly designed with the sequence 5' -atgcgactgcagctaaatggtaaaaaatcgatcaccatgttt-3', with a Pst] restriction site (underlined) designed into the 5' -end to facilitate cloning.
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen). Purified Nat2
PCR products and the PKK223-3 bacterial expression vector (Pharmacia-LKB Biotechnology,
Piscataway, NJ) (GenBank M77749) were digested with EcoR] and Pst] restriction enzymes
(New England Biolabs, Inc., Beverly, MA). The Nat3-pcDNA3.1 clone described in Chapter IV,
and the PKK223-3 bacterial expression vector were digested with Xma] and Pst] restriction
enzymes (New England Biolabs). Restriction digest products were separated by electrophoresis
on a 0.6% agarose gel, then analyzed under long wavelength UV light (365 nm).

For the

digestion of PKK223-3, the band corresponding to the open vector was excised from the gel. For
the digestion of the Nat2 PCR products and the Nat3-pcDNA3.1 vector, the appropriately sized
band (-1000 kb) was excised from the gel. The restriction digested Nat2 and Nat3 products were
then purified from the agarose gel using the Qiaex II Gel Extraction Kit (Qiagen). Ligation was
then carried out with the cut plasmid, approximately 3 molar equivalents of the insert, and T4
DNA-ligase at 37°C for 20 minutes. All clones were created in duplicate from duplicate initial
PCR reactions, and water controls were used to ensure that there were no false positive Nat bands
due to DNA contamination.
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Transformation of Competent Escherichia coli
NovaBlue competent cells (Novagen, Inc., Madison, WI) were transformed with ligation
reaction products, then plated on LB-agar plates (containing 100

~g/ml

ampicillin for selection of

E.coli containing the circular PKK223-3 vector, which contains the ampicillin resistance gene

encoding

~-lactamase)

and allowed to incubate overnight at 37°C. NovaBlue competent cells

were used as an initial cloning host due to their high transformation efficiency. Colonies were
tested for PKK223-3 plasmids containing the Nat insert by colony PCR using PKK223-3-specific
forward (5' -ttatcagaccgcttctgcgt-3 ') and reverse (5' -gctgttgacaattaatcatcgg-3') primers designed
by Dr. David Barker.

Colony PCR was performed by heat denaturing transformed E.coli

(corresponding samples were preserved by streaking on LB-agar plates and incubating overnight
at 37°C), followed by PCR using Taq polymerase (Perkin Elmer Corp). PCR products were then
subject to electrophoresis on a 1% agarose gel. The presence of Nat-sized bands (-1000 kb) in
the gel indicated the presence of the Nat insert. Water controls were used to ensure that there
were no false positive Nat bands due to DNA contamination of the PCR reagents used for the
PCR. One colony from each of the preserved successful bacterial colony streaks were used to
inoculate 200 ml of LB (100

~g/ml

ampicillin), then incubated overnight at 37°C with shaking

(225 rpm) Cells were centrifuged at 5000 x g, and plasmid DNA isolated using the Qiagen
Plasmid Midi Kit (Qiagen), and plasmid DNA quantified using a Beckman DU-650
spectrophotometer.
To verify that the correct sequence was cloned into the plasmid, both strands of the Nat
insert were sequenced using gene-specific sequencing primers. For the Nat3 clone, the primers
described in Chapter IV were used, in addition to the PKK223-3-specific reverse primer
described above. For Nat2 clones, four forward primers (5' -tctgaattcatggacattgaagcatactttgaaagaattggttat-3', 5' -tagaagtcatctttgatcaa-3', 5' -aagagaatggaacctggtac-3', cagcatccttgtttacaagt-3') and
four reverse primers (5' -atgcgactgcagctaaatggtaaaaaatcgatcaccatgttt-3', 5' -tacctgagttttaggagtta-3',
5' -agaagacagtttgctttcta-3', and 5' -acttagtacggtgacgacat-3') were used, in addition to the PKK223-
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3-specific reverse primer described above. Most of the Nat2 sequencing primers were designed
by Mark Doll. Nat2 primers do not overlap with slow Nat2 allele polymorphic sites.
Sequence-verified Nat-PKK223-3 plasmids were then transformed into competent JM 105

E.coU. JM 105 E.coli glycerol stocks were plated on LB-agar (no drug). A single JM 105 colony
was then used to inoculate 25 ml of LB (no drug), and grown to log phase by incubation at 37°C
with shaking (225 rpm). Following centrifugation at 5,000 x g for 10 minutes, pellets were resuspended in 1110 volume cold TSB medium (10% PEG, 5% DMSO, 10 ruM MgCI 2, 10 ruM
MgS0 4 , I X LB medium), and incubated on ice for 10 minutes. Cells were stored in 100 fll
aliquots at -80°C until used for transformations. Competent JM I 05 E.coli were transformed with
Nat-PKK223-3 plasmids and incubated overnight at 37°C on LB-agar (100 flg/ml) plates. The
presence of the Nat insert was again verified by colony PCR. A negative control for enzyme
assays was also created by transforming JMI05 competent E.coU with an empty PKK223-3
plasmid.

Natl *13-PKK223-3 clones were obtained from Mark Doll and transformed into

competent JM I 05 E.coli as described above.
Recombinant Expression in E.coli
From frozen stock, samples were plated on LB-agar plates (100 flg/ml ampicillin), and
incubated overnight at 37°e. Colony purification was performed by re-plating a single colony
from the overnight incubation on an LB-agar plate (l00 flg/rnl ampicillin), and incubated
overnight at 37°e. A single colony was chosen from the purification and used to inoculate 25 ml
liquid broth (100 flg/ml ampicillin), which was then incubated overnight at 37°C with shaking
(225 rpm). Subsequently, 200 rnl of LB (100 /-lg/ml ampicillin) was inoculated to an OD600 of
0.2. This inoculate was then incubated with shaking (225 rpm) for approximately 3 hours at 3TC
to an OD600 of 0.5 to 0.7. Immediately, the PKK223-3 tac promoter was induced by adding
isopropyl-beta-D-thiogalactopyranoside (IPTG) to 100 ruM, then incubated for an additional 3
hours. Following incubation, cells were immediately pelletted by centrifugation at 6,000 x g for
10 minutes, then either processed immediately or stored overnight at -20°e. Bacterial cytosols
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were prepared by sonication in

1120 volume (i.e. 10 ml for 200 ml culture) homogenization

buffer (20 mM Na3P04, 1 mM EDTA, pH7.4, I mM DTT, protease inhibitor cocktail), followed
by centrifugation at 15,000 x g. Cytosols were aliquoted into 1.5 ml tubes and stored at -80°C.
Total protein concentration was determined by the Bradford method (Bio-Rad Laboratories, Inc.,
Hercules, CA) (Bradford, 1976). Cytosols were ali quoted and stored at -80°C.
Enzymatic Activity Assays
N-acetylation activity was measured usmg bacterial cytosolic preparations containing
recombinantly expressed Natl 13, Nat2 20, Nat2 21A, Nat2 21B, Nat3, or the PKK223-3
negative control (no insert). Cytosols were incubated with 1 mM acetyl-CoA and 100 llM or 300
llM substrate for 10 minutes at 37°C. Enzymatic reactions were stopped upon addition of acetic
acid to 0.1 M to precipitate the protein. Precipitated protein was removed by centrifugation at
13,000 rpm for 10 minutes, and the remaining supernatant analyzed by high performance liquid
chromatography (HPLC) using System Gold Software (Beckman-Coulter, Fullerton, CA, USA)
for quantification of N-acetylated product. Tested compounds include the following known Nat
substrates: p-aminobenzoic acid (PABA), 4,4-methylenebis(2-chloroaniline) (MOCA), N-(paminobenzoyl) glutamate (pABG), 4,4-methylenedianiline (MDA), 4-aminobiphenyl (ABP), 2aminofluorene (AF), and sulfamethazine (SMZ).

HPLC methods for each substrate were

developed by Mark Doll.
Enzyme activities were normalized to the time of the reaction (10 minutes) and the total
protein concentration as determined by the Bradford method (Bio-Rad) resulting in units
nmoles/min/mg. Initial enzyme activity measurements were performed using the above reaction
conditions for serial dilutions (1: I, 1:5, 1:25, 1: 125, 1:625) of each recombinant lysate. For each
lysate-substrate reaction combination, the dilution that resulted in less than 15% conversion of
substrate to product was chosen to ensure that the enzyme's activity is not affected by limiting
substrate availability. Thus, activities were measured at initial rate conditions and the data are
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reported as initial velocities.
N-acetylation activity was measured for each substrate in triplicate, in addition to a noacetyl-CoA control to ensure that the reactions are acetyl-CoA dependent. The negative control
activity was subtracted from the sample activities.

Initial velocities are reported in nmoles

acetylated substrate per minute reaction time per mg total protein (nmoles/min/mg) with standard
error of the means (SEM) calculations for each.
Kinetic Parameters
To calculate Km (IlM) and V max (nmoles/min/mg) kinetic properties, initial velocities were
measured, as described above, at a minimum of six different substrate concentrations. The data
were fitted to a non-linear regression curve using GraphPad Prism V2.01 software (GraphPad
Software, Inc., San Diego, CA). V max is the maximal rate of product formation and Km is the
substrate concentration at Y2 Vmax (Michaelis-Menton Constant). A much more informative
parameter is the specificity constant, which is the rate of substrate capture, calculated as V maJKm
(Fersht, 1998). In addition to Km and V max, the specificity constant was calculated.
Thermostability Assays
Recombinant Nat J, Nat2, and Nat3 lysates were diluted to 1 )1g/ml in homogenization
buffer, then incubated at 50°C for 5, 10, 20, 40, 60, and 80 minutes. Incubated lysates were
transferred to ice immediately following the allotted time and assayed for N-acetylation activity
as described above. Activities in nmoles/min/mg were normalized to the activity prior to any
inactivation by calculating the percent original activity remaining, with the highest activity at
100%. Data were fitted to a first order decay curve using GraphPad Prism software, with which
the half-life (T y, ) and heat deactivation constant (k) were calculated.
Characterization of N-acetyltransferase Polycional Antisera for Rat Nat Detection
The specificity of various N-acetyltransferase polycional antisera for rat Natl versus Nat2
was characterized by SDS-PAGE and Western blotting using rat Nat recombinant lysates. These
antisera were also used to study the mechanism of the rat Nat2 slow alleles. To develop rat Nat3

56

polyclonal antiserum, a Nat3-specific peptide was designed based on the same strategy used for
the rat Nat1 and Nat2 polyclonal antisera production (Figure 13), then developed commercially
through Invitrogen (Carlsbad, CA, USA).
Recombinant lystaes were diluted with homogenization buffer to 2 f.Lg/ml, and then diluted
to 1 f.Lglml by adding an equal volume of 2 X Laemmli Sample Buffer (Bio-Rad). Samples were
then denatured by addition of

~-mercaptoethanol

(to 5%) and immersed in boiling water for 5

minutes. To load 20 Ilg of total protein, 20 III of I f.Lg/ml sample was loaded onto a preformed
12% polyacrylamide gel (Cambrex, East Rutherford, NJ, USA). Samples were electrophoresed at
125 V for 2.5 hours in pre-mixed 1 X Tris/Glycine/SDS electrophoresis buffer (Bio-Rad
Laboratories, Inc.). Protein bands were then electrically transferred from the polyacrylamide gel
to Hybond-ECL nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA) at 100
V for 1 hour using pre-mixed 1 X Tris/Glycine transfer buffer (Bio-Rad). The membrane was

blocked overnight at 4°C using Blocker BLOTTO in TBS (Pierce Biotechnology, Inc. Rockford,
IL). The membrane was then washed 3 times for 10 minutes each time with wash buffer (25 mM
Tris, 0.15 M NaCI, pH 7.2) (Pierce). The membrane was blotted with blocking buffer, 0.05%
Tween 20 and primary antisera (diluted 1:2000) for 2 hours at room temperature. Following
another wash cycle (3 x 10 minutes), the membrane was blotted with blocking buffer, 0.05%
Tween 20, and goat anti-rabbit horseradish peroxidase-conjugated secondary antibody
(Amersham) diluted 1:50,000 for 1 hour at room temperature. Following another wash cycle (3 x
10 minutes), the membrane was incubated in working chemiluminescent solution for 5 minutes
using an ECL detection kit (Amersham Biosciences) exposed to Kodak Bio-Max film.
Six different N-acetyltransferase antisera, in addition to the newly developed Nat3
antibody were tested using the above method. The negative control cytosols (lysates of E.coli
transformed with empty PKK223-3) were used as negative controls for the Western blot, and
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Peptide Design for Rat Nat Antibodies

A

Natl
Nat2

N- VLKTTFG I SLEKKFVPKHGELVFTI-C
N-VLKT I FGVSLERKLVPKHGDRFFTI-C

B

Natl
Nat3

N-VLKTTFGI SLEKKFVPKHGELVFTI-C
N-VLKRVFGI RLETKLVPKCGNWLFTI-C

C

Nat2
Nat3

N- VLKTI FGVS LERKLVPKHGDRFFTI-C
N-VLKRVFG IRLETKLVPKCGNWLFTI-C

Figure 13. Peptide Design Strategy for Nat3-specific Polyclonal Antibody Development
Rat Nat I and Rat Nat2 polyclonal antisera were produced previously using a peptide identical to the
C-terminal rat Nat I and Nat2 amino acid seque nce. Since these antibodies successfully recognize their

targets, this strategy was mimicked in designing peptide for producing rat Nat3-specific polyclonal
antiserum . The peptide used for production of a Nat3 ant ibody originated from the C-terminal end of the
Nat3 amino acid sequence. (A) The Natl and Nat2 peptides (underlined) differ by onl y six of the 17 amino
ac ids shared between the two. (B) The rat Nat I and Nat3 peptides differ by seven of the 16 am ino acids
shared between the two, and also differ by additional three N-terminal amino ac ids in the Nat3 peptide and
one additional am ino acid on the N-terminal end of the Nat I peptide. (el The rat Nat2 and Nat3 peptides
differ by eight of the 16 amino acids shared between the two, and also differ by an additional three Nterminal amino acids in the Nat3 peptide. Since the differences between Nat3 and Nat I , and between Nat3
and Nat2 are greater than the differences between Nat I and Nat2, the resulting Nat3 polyclonal antiserum
should be as select ive as the Nall and Nat2 antisera since it provides a seemingly sufficient number of

Nat3-specific epitopes.
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yeast cytosols containing recombinantly expressed NATI and NAT2 were used as the positive
controls.

Quantitation of Nat bands was achieved by normalization to non-specific bands.

Protein bands were analyzed by densitometry.
Bacterial RNA Isolation
Total bacterial RNA was isolated from 1M I 05 E.coli using the RNeasy Kit from Qiagen.
To test for quality, RNA was separated by electrophoresis on a 1% agarose gel and analyzed for
distinct 23S and 16S bacterial ribosomal RNA bands. DNA was removed from the RNA samples
using the Turbo DNase kit from Ambion (Austin, TX), then re-analyzed by electrophoresis to
confirm disappearance of DNA contamination, as is evident by the high molecular weight DNA
bands visible at the top of the agarose gel.

During this electrophoresis step, RNA was also

quantified by including RNA standards in known amounts (200 ng, 400 ng, 800 ng). The bands
were quantitated by densitometry. The concentration of the samples was then calculated using a
standard curve. RNA samples were stored at -80°C.
Real-Time RT-PCR
Bacterial RNA was reverse transcribed to cDNA using SuperScript III First-Strand
Synthesis System for RT-PCR from Invitrogen (Carlsbad, CA). Control reverse transcription
reactions were performed in the absence of reverse transcriptase as controls for DNA
contamination. The reaction mixture contained newly designed rat Nat-specific TaqMan primers
(forward, 5' -agatgtgggagcctctggaatt-3'; reverse, 5' -gcaggcacctgag-3') from Applied Biosystems
(Foster City, CA), a VIC-labelled rat Nat2-specific fluorogenic MGB probe (5' -cttccctgatgttaattc3') from Applied Biosystems, bacterial cDNA and TaqMan Universal PCR Master Mix from
Applied Biosystems, which contains AmpliTaq Gold polymerase. Real-time PCR was performed
using an ABI Prism 7700 sequence detection system from Applied Biosystems. The reaction
conditions used for real-time PCR were previously described (Doll and Hein, 2002). Total RNA
concentration was used to normalize the real-time PCR data.
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Results & Discussion

Cloning, Transformation and Recombinant Expression
The coding exon of rat N-acetyItransferases NatJ*J3, Nat2*20, Nat2*21A, Nat2*21B,
and Nat3 were successfully cloned into bacterial expression vector PKK223-3 (Pharmacia), as
verified by sequencing with primers that span the entire top and bottom strands of the Nat
sequence as well as the 5'- and 3'- sequence-vector interfaces. Successful transformation of
JM 105 E.coli with each clone was verified by the ampicillin resistance that PKK223-3 conferred
to the successfully transformed bacteria, and subsequently by colony PCR with gene- and
plasmid-specific primers and gel electrophoresis.

Recombinant expression was successful as

verified by measurement of N-acetyItransferase activity in Iysates and by immunoreactive
detection using Nat-specific polyclonal antibodies.

Bacterial expression vector PKK223-3

without insert was used as a negative control beneficial for cloning, transformation, and
recombinant expression verification.
Enzymatic Activity Assays
N-acetylation activity was measured using recombinantIy expressed Natl*13, Nat2*20,
Nat2*21A, Nat2*21B, and Nat3.

Initial velocities were measured as described above for

substrates p-aminobenzoic acid (PABA), 4,4-methylenebis(2-chloroaniline) (MOCA), N-(paminobenzoyl) glutamate (pABG), 4,4-methylenedianiline (MDA), 4-aminobiphenyl (ABP), 2aminofluorene (AF), sulfamethazine (SMZ) (Figures 14-17).
Initial velocity measurements confirmed that rat Nat3 is a functional N-acetyItransferase
enzyme with distinct substrate selectivity, but with relatively low activity. Nat3 catalyzed the Nacetylation of ABP, AF, MDA, and MOCA at low levels relative to Natl and Nat2, with its
highest activity toward MDA and lowest activity toward MOCA. Nat3-catalyzed N-acetylation
products were not detected with substrates pABG, PABA, and SMZ. No Nat3 selective substrate
could be identified from the substrates tested.
Natl catalyzed the N-acetylation of every substrate tested, with the exception of pABG.
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N-acetylation of p-aminobenzoic acid (PABA)

A

Not
Detected

Nat1

Nat2 20

Nat2 21A

Nat2 21B

Nat3

N-acetylation of sulfamethazine (SMZ)

B

Not
Detected

Nat2 21A

Nat2 21B

Nat3

Figure 14. Rat Nat N-acetylation of PABA and SMZ
Enzymatic activities were measured in triplicate. Error bars represent the standard error of the
means. (A) PABA is selectively acetylated by rat Nat2 20 (very low activity for rat Natl not visible on
graph) over Natl, and Nat3 acetylation of PABA was not detected. (B) SMZ slightly prefers acetylation
via Nat!, although Nat2 activity is substantial. Nat3 acetylation of SMZ was not detected. A significant
difference between the activities of two Nat2 slow enzymes was observed for both PABA (p < 0.0001) and
SMZ (p < 0.0001).

61

N-acetylation of 4,4'-methylenedianiline (MDA)

A

Nat221A

Nat2218

Nat3

N-acetylation of 4,4'-methylenebis(2-chloroaniline) (MOCA)

B

Nat2 21A

Nat2 218

Nat3

Figure 15. Rat Nat N-acetylation of MDA and MOCA
Enzymatic activities were measured in triplicate. Error bars represent the standard error of the
means. (A) MDA is selectively acetylated by Nat2 20. Nat3 acetylation was detected, resembling the
activity of a Nat2 slow acetylator enzymes. (B) MOCA is selectively acetylated by Nat!. Nat3 activity
was detected for MOCA at levels similar to Nat2 slow acetylators. A significant difference between the
activities of the two Nat2 slow enzymes was observed for both MDA (p < 0.0001) and MOCA (p <
0.0001).
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N-acetylation of 4-aminobiphenyl (ABP)

A

0-0'
~

Nat2 21A

Nat221B

j)

_

NH2

Nat3

N-acetylation of 2-aminofluorene (AF)

B
c

~...
c..
Cl

~

'f

i!:

«~

VI

Q)

'0
E
c

Nat2 21A

Nat2 21B

Nat3

Figure 16. Rat Nat N-acetylation of ABP and AF
Enzymatic activities were measured in triplicate. Error bars represent the standard error of the
means. (A) ABP is a selective substrate for Nat2 20, but with substantial activity also via Natl. Nat3
acetylation of ABP was detected at a rate similar to the Nat2 slow enzymes.

(B) AF is selectively

acetylated by Nat2. Nat3 acetylation of AF was detected at a rate similar to the Nat2 slow alleles. A
significant difference between activities of the two Nat2 slow enzymes was observed for both ABP (p <
0.0001) and AF (p = 0.0007).
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N-acetylation of N-(p-aminobenzoyl)glutamate (pABG)

Not
Detected

Not
Detected

Nat1

Nat3

Figure 17. Rat Nat N-acetylation of pABG
Enzymatic activities were measured in triplicate. Error bars represent the standard error of the
means. The potentially endogenous Nat substrate pABG was selectively acetylated by Nat2 enzymes with
no activity detected for Natl or Nat3. The ratio of Nat2 rapid to Nat2 slow activities is much smaller here
than for the other substrates tested, for unknown reasons. A significant difference between the Nat2 slow
acetylator enzymes was observed (p = 0.0001).
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Natl demonstrated the highest catalytic activity toward MDA, though MOCA was most
selectively N-acetylated by Nat!.

According to the comparison of ammo acids residues

influential on substrate selectivity (Figure II), it might be expected that rat Natl would mimic the
substrate preference of human NAT2. The human NAT2 selective substrate SMZ (Grant et ai.,
1991) was acetylated at a higher rate by rat Nat I than Nat2, though not to the degree required for
classification as a rat Natl selective substrate. MOCA appears to be a superior rat Natl selective
substrate, both for its selectivity and relatively high catalytic activity, and should be used for in

vivo studies of rat Natl enzymatic activity instead of SMZ. The apparent difference in SMZ
substrate preference between human NAT2 and rat Natl may reflect the influence of other
differences between the enzymes that also playa role in substrate selectivity.
For all substrates tested, rat Nat2 20 was a rapid acetylator relative to Nat2 21A and Nat2
2IB, which were slow acetylators.

This relationship is consistent with previous findings

regarding these rat Nat2 enzymes (Doll et ai., 1995; Doll and Hein, 1995).

All three rat Nat2

enzymes acetylated every substrate tested, though all three acetylated PABA at the highest rate;
in fact, PABA was highly selective for rat Nat2 over Natl and Nat3.

This relationship is

consistent with the comparison in Figure II, since PABA is selective for human NATI over
NAT2, confirming the suspected correlation between the substrate selectivities of rat Nat2 and
human NAT 1. Of those substrates tested, PABA is the clearly the substrate of choice for studies
of rat Nat2 activity in vivo.
An apparent paradox is observed in the difference between the activities of slow
acetylators Nat2 21A and Nat2 2IB. This difference has been observed with multiple different
clones by different people and at different times (Hein et ai., 1997). The observed differences are
significant (GraphPad Prism unpaired t-test) for all substrates tested; ABP (P < 0.0001), MDA (P

< 0.0001), MOCA (P < 0.0001), PABA (P < 0.0001), pABG (P =0.0001), SMZ (P < 0.0001), AF
(P

= 0.0007).

Since these enzymes are identical in their primary amino acid sequence, the

different activities suggest differences at the level of transcription and/or translation. Since the
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differences between the two alleles at the nucleotide level are silent (GmA in Nat2*21A; C 672T in

Nat2*21B), one or both of these silent nucleotide polymorphisms may contribute to the activity
difference between the al1eles. This activity difference could come by way of alternative codon
usage and/or alterations in mRNA expression and/or structure.

This issue will be addressed

further in experiments to follow.
Kinetic Parameters
The Michaelis-Menten constant (KnJ, the maximum velocity (V max), and the specificity
constant (V/K) were calculated by fitting the data to a non-linear regression curve using
GraphPad Prism software for the acetylation of AF by Natl 13, Nat2 20, Nat2 21A, Nat2 21B,
and Nat3 (Figure 18), and of ABP for Nat I 13, Nat2 20, and Nat3 (Figure 19).

The data

demonstrate substrate-dependent Nat catalytic activity.
N-acetylation of AF is accomplished most efficiently at all substrate concentrations by
Nat2 20, which has both the largest V max and the largest specificity constant. The other rat Nats
have comparable V max values to one another, with Nat3 having the lowest of them all. The two
slow Nat2 enzymes have the lowest specificity constant due to their relatively large Km values,
although they have higher V max values than Nat3; Nat3 apparently acetylates AF better than the
Nat2 slow alleles at lower concentrations, but the Nat2 slow enzymes are more efficient
acetylators than Nat3 at relatively higher concentrations.
Nat2 slow acetylator polymorphisms appear to both reduced V max and increased Km of the
enzymes, resulting in a smaller selectivity constant. The reduced V max may indicate reduced
protein, though that should be confirmed with a Western blot analysis. Here, the apparent
difference in activity between the Nat2 slow enzymes (Figures 14-17) manifests itself as
significant differences in V max. but not Km. Reduced V max suggests reduced protein for Nat2 21 A
relative to Nat2 2IB. Reduced Nat2 21A protein should be confirmed by Western blot.
ABP is N-acetylated most efficiently by Natl at relatively low concentrations and by
Nat2 at relatively high concentrations. Although Nat 1 has smaller V max than Nat2, it has a higher
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992 ± 126
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1.13
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Figure 18. Kinetics of Rat Nat N-acetylation of 2-Aminofluorene (AF)
Rat N-acetyltransferases acetylate 2-aminotluorene with varying kinetics. Initial velocities were
measured in triplicate (error bars and "±" values following data indicate SEM) for various dilutions of
substrate. The non-linear regression fit and the calculated kinetic constants for each enzyme are shown
above. The original location of the inset magnified portion is surrounded with a dotted line.

Nat2 20

acetylates AF most efficiently, followed by Nat! and Nat3. Nat2 slow alleles have the lowest specificity
constants due to their high Km values.
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N-acetylation of 4-aminobiphenyl (ASP)
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Nat220
Nat3

34.0 ± 1.8

Michaelis-Menten Constant
Km (11M)

706 ±50

5.83 ± 1.05
1574 ± 213

4.33 ± 0.10

18.2 ± 1.6

Specificity Constant
Vmax/Km (nmoles/minlmg/I1M)

5.83
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Figure 19. Kinetics of Rat Nat N-acetylation of 4-Aminobiphenyl (ABP)
Initial velocities were measured in triplicate (error bars and "±" values following data indicate
SEM) for various substrate dilutions. The non-linear regression fit and the calculated kinetic constants for
the data are shown above. The original location of the inset magnified portion is surrounded with a dotted
line. While Nat2 20 has the largest V max, Natl has the largest specificity constant for AF N-acetylation; at
relatively low substrate concentrations, Natl is a more efficient acetylator of ABP than Nat2, whereas the
opposite is true at higher ABP concentrations. Nat3 has relatively low V max and selectivity constant.
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specificity constant. Nat2 has the largest V max, but also has a very large K m, resulting in a smaller
specificity constant than Natl. Nat3 has the smallest specificity constant, but acetylates ABP at
Nat I-saturating substrate concentrations.
These kinetic characterizations of recombinant rat enzymes

10

an artificial bacterial

system are useful for general comparisons of the enzymes' activity and stability, but are limited in
application since they do not necessarily reflect the characteristics of the enzymes in vivo.
Thermostability
Structural stability of the rat Nat enzymes was tested as thermostability (Figure 20). Nat I
is the most stable of all rat Nat isozymes, showing no decrease in its activity after 80 minutes
incubation at 50D C. Rat Nat3 is less stable than Nat I , having lost most of its activity by 80
minutes of incubation, but considerably more stable than any of the Nat2 alleles. Nat2 20 is very
unstable, having lost most of its activity within 5 minutes of incubation.
The Nat2 slow alleles have reduced thermostability relative to Nat2 20. In fact, the rates
of inactivation are so high that their activity was completely eliminated before the first time point
(5 minutes) was taken. Significance between the inactivation rates of the two slow alleles could

not be tested due to the rapid drop off of the enzyme activity following incubation. This was not
pursued further since the two slow alleles produce identical enzymes.
These data are consistent with inactivation data reported previously for all rat Nats except
Nat3, which was not known at the time (Gray et aI., 1996). Here, it was determined that stability
from highest to lowest is Nat1 » Nat3 > Nat2 20 > Nat2 21A/21B. The general relationship
between Nat1 and Nat2 thermostability (Natl»Nat2) shows an inverse correlation with human
NATI and NAT2 enzymes, where human NAT2 is much more stable than human NATl.
Reduced enzymatic stability is apparently part of the mechanism for slow Nat2 acetylator
phenotype.
Characterization of N-acetyltransferase Antisera for Rat Nat Detection
A

number

of polyc1onal

antibodies
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Figure 20, Thermostability of Recombinant Rat N-acetyltransferases
Recombinant rat N-acetyltransferases were heat inactivated by incubation in at 50°C for 0, 5, 10,
20, 40, 60, 80 minutes, then assayed for N-acetylation of 2-aminofluorene.

Resulting N-acetylation

activities were normalized to the enzyme's original activity prior to incubation (time

= 0).

In the plot

shown above is a non-linear fit for one phase exponential decay (GraphPad Prism), with 100% on the Yaxis represents the activity prior to incubation. Rat Natl is highly stable, with no detectable decrease in
activity during the entire incubation. Rat Nat3 is of intermediate stability. The rat Nat2 enzymes, however,
are very unstable, with Nat2 20 losing most of its activity within the first five minutes of incubation, and
Nat2 21A and Nat2 2IB losing their activity almost immediately upon incubation.
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N-acetyltransferase enzymes by Western blot. These include human, murine, hamster, as well as
rat polyclonal antisera. The Nat3-specific polyclonal antiserum recently obtained from Invitrogen
was included in these analyses. Once characterized, successful antibodies will be utilized for
detection of Nats in tissues, where the concentration of Nat enzymes may be relatively low.
Since rat tissues contain complex mixtures of multiple rat Nat isozymes, it is important that the
antisera are isozyme-specific. Recombinant Iysates containing rat Natl 13, Nat2 20, Nat2 21A,
Nat2 21B, and Nat3 offer the benefit of high Nat expression. Individually expressed recombinant
rat Nats in a high-expression system is ideal for characterization of these antibodies. For the first
time, all seven polyclonal antisera were characterized for rat Nat 1, Nat2, and Nat3 specificity by
Western blot (Figure 21).
The polyclonal antibodies raised against rat Natl were sufficiently specific for rat Natl
versus Nat2, and likewise the polyclonal antibodies raised to rat Nat2 were sufficiently specific
for rat Nat2 versus Nat 1. The newly designed and produced rat Nat3 antiserum did not detect any
of the rat Nats under the conditions tested. Of the other antibodies tested, one did not detect any
of the rat Nats (human NAT2), and the rest of them detected both enzymes (hamster Nat2, mouse
Nat 1, mouse Nat2) to varying degrees. Since these antibodies were tested with bacterial cytosols,
their specificity with regard to non-specific bands in rat tissues is not known, and background
bands in these bacteriallysates are not of practical importance to this study.
The rat Nat3 antiserum titer as determined by the company that developed the antibody
(Invitrogen) indicates that polyc\onal Nat3 antibodes are present in the antiserum in amounts
comparable to the rat Nat! and Nat2 antibodies in their antisera, although there are no guarantees
that the antiserum will work for Western blotting. More Western blotting conditions should be
tested to further characterize the Invitrogen Nat3 antiserum.

The dilution of antibody,

concentration of tween 20, time and temperature of incubation, and time of film exposure should
be optimized to attempt to detect recombinant Nat3 using this antiserum.
Since the epitope for rat Nat2 polyclonal antiserum production is located at the C-
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Figure 21. Polyclonal Antisera Detection of Rat N-acetyltransferases by Western blot
Recombinant Iysates containing rat Natl 13, Nat2 20, and Nat3 were analyzed by Western blot
using the available polycJonal antisera.

The negative control is from Iysates of recombinant E.coli

expressing empty PKK223-3 vector. The rat Natl polycJonal antiserum selectively recognizes Natl over
Nat2 and Nat3, with a very small band for Nat2

«

2% of the Natl band). The rat Nat2 antiserum

specifically recognizes Nat2 over Nat I and Nat3. Unfortunately, the newly developed rat Nat3 antiserum
was unsuccessful at recognizing any of the rat Nats under the conditions tested. Other antisera recognized
either none of the rat Nats or both rat Nat I and Nat2 to varying degrees. Mouse and hamster antibodies
were obtained from Edith Sim, University of Oxford, UK.
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terminus of the protein (Figure 13), and since none of the slow Nat2 polymorphisms affect amino
acids region (there are only two amino acid differences between the rapid allele and either of the
slow alleles), it is reasonable to think that all three Nat2 enzymes will provide identical epitopes
for antibody detection. Therefore, any differences observed by densitometric analysis between
the amounts of the rapid Nat2 enzyme and the two slow Nat2 enzymes will reflect a real protein
difference and not a difference in the number of epitopes provided by the rapid enzyme versus the
slow enzymes.
The Nat2 Slow Acetylator Mechanism
The mechanism behind the Nat2 slow acetylator alleles is unknown, and thus more
experiments are required. Kinetic measurements (Figure 18) and thermo stability measurements
(Figure 20) suggest that Nat2 21A and Nat2 21B protein levels are reduced compared to Nat2 20
protein. A Western blot of recombinantly expressed Nat2 enzymes using the rat Nat2-specific
polyclonal antiserum clearly revealed that Nat2 slow acetylator alleles do in fact have
dramatically reduced protein levels compared to Nat2 20 (Figure 22). Combining what is known
about Nat2 slow acetylator kinetics, thermostability, and protein level, points to the conclusion
that Nat2 21A and Nat2 2IB protein are reduced due to decreased thermo stability (Figure 20),
and the catalytic capability of the enzyme is reduced due to increase Km (Figure 18), the
combination of which results in slow acetylator status.
In addition to the difference between rapid and slow rat Nat2 catalytic activities,

significant catalytic activity differences were observed between the cytosols expressing the two
slow Nat2 alleles (Figures 14-17). The difference is also suggested by Western blot (Figure 22),
in which the Nat2 bands are normalized to non-specific bands; nonspecific bands should be
present in equal amounts across all samples in the same expression system. However, another
Western blot must be performed and normalized to a bacterial housekeeping gene, or some other
normalizing factor, to ensure that the small difference between recombinantly expressed Nat2
21A and Nat2 2IB protein is real and significant.
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Immunoreactive Detection of
Recombinantly Expressed Nat2 Protein

_Nat2
_Loading
Control

Figure 22. Immunoreactive Detection of Recombinantly Expressed Rat Nat2 Enzymes
Recombinant Iysates containing Nat2 20, Nat2 21A, and Nat2 21B were analyzed by SDS·PAGE
and Western blot. NatZ bands and a set of nonspecific bands were quantitated by densitometric analysis.
Nat2 bands were normalized to the nonspecific bands, which were used as a loading control. Nat2 slow
alleles produce drastically less protein in this system than the Nat2 rapid alleles. An apparent significant
difference exists between the expression of the Nat2 slow enzymes. These data need to be confirmed by a
Western blot normalized to an internal control, or other normalizing standard.

74

Recombinant Nat2 mRNA Expression

..l---

O.Ox10·OO

Nat2*20

Nat2*21A

Nat2*21B

Figure 23. Real-time RT-PCR Analysis of Recombinantly Expressed Rat Nal2 mRNA
Total bacterial RNA containing recombinant Nat mRNA was subjected to real-time RT-PCR. The
same primers and Nat2-specific fluorogenic probe were used for detection of all three alleles.

The

differences observed among the three alleles are not reflective of activity or apparent protein differences.
The total mRNA levels do not reflect the corresponding enzyme activities, indicating that differences in
mRNA expression do not cause the slow acetylator phenotype. In addition, the differences between the
two slow acetylator alleles in activity, and possibly also protein, are not reflected in these mRNA
expression data, but rather the opposite trend is observed.

While the apparent reduction in mRNA

expression for the slow alleles is numerically significant, it is most likely an artifact of the real-time PCR
method.
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The influence of Nat2 slow allele polymorphisms on mRNA expression was tested by
real-time RT-PCR (Figure 23). These data show that the affect of Nat2*21A and Nat2*21B
polymorphisms on protein expression level cannot be explained by reduction in mRNA
expression. They also show that the apparent difference between Nat2 2lA and Nat2 2IB protein
expression is not due to transcriptional differences, since the opposite trend is suggested. The
apparently significant difference between mRNA levels for the rapid allele and the two slow
alleles could be related to differences in real-time PCR efficiency, since the G 399A polymorphism
in Nat2*21A and Nat2*21B is within a region to which one of the PCR primers anneals, thereby
reducing PCR effIciency for the slow alleles.
Thus, if the protein expression differences can be verified by a Western blot analysis
normalized to a bacterial internal standard, the mRNA data indicate that in this system the silent
SNPs that characterize the Nat2 slow alleles influence translation of the Nat2 21A and Nat2 21B
enzymes. Possible translational differences might be caused by differences in codon usage and
availability in this system, or altered mRNA structure which could result in differences in
translational efficiency.
Codon usage in E.eoli was analyzed based on the two codons that differ between the two
slow alleles (Table 1) (Fuhrmann et ai., 2004; Nakamura et aI., 2000). This analysis led to the
conclusion that the opposite trend (Nat2 21A > Nat2 221 B expression) would be expected if
codon usage differences significantly influenced the translational efficiencies of the Nat2 *21 A
and Nat2*21B mRNAs. In addition, the codon usage is practically reversed in rattus norvegieus
for one of the codon pairs, indicating that if there were an influence of codon usage on
translational efficiencies in the recombinant system it would be reversed in vivo.
Since codon usage is apparently not involved in modifying translational efficiencies,
recombinant mRNA sequences (Figure 24) were analyzed for folding differences using the Mfold
program (Figure 25) (Mathews et ai., 1999; Zuker, 2003). Although the polymorphisms that
distinguish Nat2*21A (G 522A) from Nat2*21B (C 672T) are silent in the amino acid sequence ofthe
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Amino
Acid

Codon
Sequence

Fraction

Fraction

(E.mU)

(Rat)

Rat Nat2
Allele

Ser
Ser

TCC
TCT

0.15
0.17

0.23
0.18

2*21A, (2*20)
2*21B

Glu
Glu

GAA
GAG

0.67
0.33

0.39
0.61

2*21A
2*21B, (2*20)

Table 1. Codon Usage Comparison for Nat2*20, Nat2*21A, and Nat2*2IB
To analyze the possible influence of differences in codon usage on Nat2*21A and Nat2*21B
enzyme activity and possibly protein expression, the usage of the relevant codons was compared for this
system. To test the correlation of any codon usage differences in this E.coli system to an in vivo rat model,
the fraction of these codons for rattus norvegicus was also compared. Since the fraction of the GAA codon
in E.coli is twice the fraction of GAG, codon usage comparisons suggest that Nat2 *21A might be expressed
more readily than Nat2*21B, which is the reverse of what is observed experimentally. Although the Serine
codon trend is correct, the difference between them is small and not likely significant. The codon usage in
rat seems to be the reverse of what is seen in E.coli, suggesting that any effect of codon usage in this
recombinant system would be negated in vivo.
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A

Tac Promoter (PtacD
5'-gagctgttgacaattaatcatcggctcgtataatgtgtgg~attgtgagcggataacaatttcacacagga

aacagaattcccggg-3'

B

rrnB T 1 Ribosomal Terminator
5'-ctgcagccaagcttctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcag
aagcggtctgataaaacagaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcag
aagtgaaacgccgtagcgccgatggtagtgtggggtctccccatgcgagagtagggaactgccaggcatx~~~~

,~.~.~~xg~~~.9.9x.t:.x~gt.9,ga~ag~9.t.9.9gXs:;,ht.t.9.9.t:.$;hh~.t.9.t:.g- 3 '

c

Nat2*21AIPKK223·3 mRNA
5'-~attgtgagcggataacaatttcacacaggaaacagaattcccgggATGGACATTGAAGCATACTTTGAAA

GAATTGGTTATCAGAGTTCCAGGAACAAACTGGACTTGGAAGAATTAACTGAAATTCTTCAACACCAGATACGG
GCTATTCCCTTTGAAAACTTGAACATCCATTGCGGGGAATCCATGGAGCTGAATTTAGAAGTCATCTTTGATCA
AGTTGTGAGGAAGAAGCGTGGTGGATGGTGTCTCCAGGTTAATCATCTGCTGTACTGGGCTCTGACCAAAATGG
GCTTTGAAGCCACAATGTTGGGAGGGTATGTCTTTAACACTCCAGCCAATAAGTACAGCAGTGGCATGATTCAC
TTACTAGTGCAGGTGACCCTCAGTGGAAAGGACTACATTATTGATGCTGGGTTTGGACGTTCCTACCAGATGTG
GGAACCTCTGGAATTAACATCAGGGAAGGATCAGCCTCAGGTGCCTGCCATCTTTCGTTTGACAGAAGAGAATG
GAACCTGGTACTTGGACCAAATCAGAAGAGAGCAGTATGTTCCAAACCAAGAATTTGTTAACTCAGACCTCCTT
GAAAAGAACAAATATCGAAAAATCTATTCCTTTACTCTTGAGCCCCGCACTATTGAGGATTTTGAGTCCATTAA
TACCTATCTTCAGACATCGCCAGCATCCTTGTTTACAAGTAAATCATTTTGTTCCTTGCAGACCCTAGAAGGGG
TTCACTGTTTGGTTGGCTCCACCCTCACTTATAGGAGATTCAGTTATAAGGACAATATAGATCTTGTAGAGTTT
AAGAGTCTGACTGAGGAAGAAATAGAAGACATACTGAAAACTATATTTGGGGTTTCTTTAGAGAGAAAGCTTGT
GCCTAAACATGGTGATCGATTTTTTACCATTTAGctgcagccaagcttctgttttggcggatgagagaagattt
tcagcctgatacagattaaatcagaacgcgaagcggtctgataaaacagaatttgcctggcggcagtagcgcgg
tggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcccgatggtagtgtggggtctccccatg
cgagagtagggaac tgccaggca t,9.~.M$;~~~~9.9~~!\9g<?t.9~g$;s:;,ga~ - 3 '

Figure 24. Constructed Sequence of Recombinant Nat2 mRNA from PKK223-3
Promoter and terminator sequences from the PKK223-3 bacterial expression vector sequence
(Genbank M77749) were added to the 5'-and 3'-regions (respectively) of the Nat genes for analysis of
predicted mRNA structures (Figure 25). (A) PKK223-3 contains an E.eoli tac promoter of the sequence
shown (Amann et aI., 1983; De Boer et aI., 1983). The tae promoter start site is underlined (solid), and
the Xmal restriction site is underlined (dashed). (B) PKK223-3 contains an rmB T,T 2 ribosomal
terminator (Brosius et aI., 1978). These constructs were designed based on termination use of the T,
terminator (double underline) (Orosz et aI., 1991). The Pstl restricion site used for cloning is underlined
(dashed) and the suspected termination codon underlined (solid) (Lyakhov et aI., 1997). (C) Suspected
mRNA sequence for recombinantly expressed Nat2*2lA, with PKK223-3 promoter and terminator
sequences in lower case (bold).
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Nat2*21A

Nat2*21B

Figure 25. Mfold Predicted mRNA Structures for Recombinant Nal2 Slow Alleles
The RNA folding prediction software, Mfold, was used to predict the mRNA structures of
recombinantly expressed rat Nat2*2JA and Nat2*21B.

Differences between the predicted mRNA

structures are circled, with the associated polymorphism indicated where appropriate. These two alleles
differ only by these two nucleotide changes, which are silent in the amino acid sequence. While this
structure prediction does not take into account the tertiary structural interactions within the mRNA species',
it gives some clues about what might happen to the secondary structure. The influence of the 0 522 A
polymorphism in Nat2 *21 A may be to reduce the complexity of the folding slightly, whereas the influence
of the C672T polymorphism in Nat2 *21 B seems to relax some of the structural complexity in that region.
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coded proteins, they may have some influence on mRNA folding (Shen et a\., 1999) and thereby
influence mRNA stability (Capon et a!., 2004) or translational efficiency. The Mfold server
predicts folding changes associated with the two polymorphisms that distinguish the aIleles. The
522

G A polymorphism in Nat2*21A may reduce the complexity of the folding slightly relative to
the Nat2*21A structure. On the other hand, the C672T polymorphism in Nat2*21B seems to
release many of the structural folds in that region, relative to Nat2*21B. A change to lower
complexity in this region affected by the C672T polymorphism is consistent with an increased
translational efficiency for this allele, since ribosomal unfolding of this section might require less
energy and time during translation. This change may also be consistent with a slightly decreased
mRNA stability for the Nat2*21B recombinant mRNA, as suggested with real-time RT-PCR
analysis (Figure 23). This would require the Nat2*21 B silent mutations to be more influential
(relative to Nat2*21A) on translational efficiency than on mRNA stability. Due to the complex
nature of an mRNA molecule, these predicted mRNA structures amount to speculation, an
educated guess, and verification would require further experiments; such experiments are beyond
the scope of this study and will not be performed.
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Conclusions

Rat Natl*13, Nat2*20, Nat2*2IA, Nat2*2IB, and Nat3 genes encode functional Nat
enzymes with characteristic substrate selectivities, catalytic activities, and thermostabilities in

vitro. MOCA is the best Natl-specific substrate, and PABA is the best Nat2-specific substrate.
Although Nat3 is a functional N-acetyltransferase, it has relatively low activity toward every
substrate tested and no comparable human N-acetyltransferase gene.

Future in vivo Nat

expression studies using rats need not include rat Nat3, since it does not appear to significantly
influence overall N-acetylation and is relatively unrelated to human NATs.

However, Nat3

mRNA expression should be measured to verify that low rat Nat3 activity is not compensated for
by high Nat3 expression in vivo.
A correlation exists between rat Natl and human NAT2, and between rat Nat2 and
human NATI.

Evidence for this correlation was found in sequence similarity (Figure II),

substrate selectivity (Figures 14-17), and thermostability (Figure 20). These similarities indicate
that the rat is a suitable model for in vivo N-acetyltransferase studies.
Rat Nat antisera are sufficiently specific for rat Natl and Nat2 (Figure 21). The newly
designed and developed rat Nat3 antiserum was unsuccessful at identifying any of the rat Nats at
the conditions tested.
The mechanism of the rat Nat2 slow acetylators, Nat2 21A and Nat2 21B, involves
elevated K m , thus reduced specificity constant (Figure 18), and reduced protein (Figure 22) due to
reduced enzyme stability (Figure 20). Due to the polymorphic nature of rat Nat2, rats may serve
as useful in vivo rapid and slow acetylator models.
Although the Nat2 slow alleles differ only by silent nucleotide polymorphisms, their
enzymatic activities differ significantly (Figures 14-17) possibly due to significant differences in
protein expression (Figure 22). The possible differences in protein expression are not due to
differences in mRNA transcription or mRNA stability (Figure 23).

Possible translational

differences cannot be explained by codon usage (Table 1), but they may be explained by
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differences in translation efficiency due to differences in mRNA folding (Figure 25).
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Future Experiments

Of the substrates tested, PABA, SMZ, MOCA, MDA, and pABG need to be tested for
kinetic parameters
including

Km

and V max'

p-aminoacetanilide,

Additional prospective substrates have been identified,

3-amino-4-methoxyacetanilide,

3-ethylaniline,

2-amino-5-

nitrophenol, 4-amino-2-nitrophenol, 2,6-dimethylaniline, o-toluidine, and 3,5-dimethylaniline.
These wiIl also be assayed for N-acetylation. Metabolic activation assays will be performed on
N-OH-PhIP and N-OH-ABP with the new HPLC method developed by Mark Doll.
Instead of relying on previously published data regarding human NAT activity, a more
direct comparison of human NATl and NAT2 versus rat Nat! and Nat2 may be necessary.
Human NATs will be recombinantly expressed in the same bacterial system using expression
plasmids designed previously in this lab by Mark Doll, and assayed with substrates PABA and
MOCA, which are rat Nat2 and Nat! selective, respectively. This will allow direct comparison of
rat Nats to human NATs expressed in the same system.
Optimization of Western blotting conditions will be tested to determine whether the Nat3
antiserum will be useful for Nat3 detection. In addition, the rat Nat antisera will be tested for
their detection of rat Nat proteins in vivo. Western blot will also be performed on the rat Nat2
recombinant lysates and normalized to an internal standard. Since protein expression of the two
slow alleles is very similar, the difference must be verified by normalization to an internal
standard.
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CHAPTER VI
TISSUE-SPECIFIC EXPRESSION OF RAT N -ACETYLTRANSFERASES:
DISSERTATION AIMS AND EXPERIMENTAL METHODS

Introduction

The goal of my dissertation project is to investigate the influence of genetic background
and cigarette smoke exposure on rattus norvegicus N-acetyltransferase 1 (Natl) and 2 (Nat2)
mRNA and protein expression in various tissues. These studies will utilize rats as in vivo models
to characterize and predict a mechanism for human N-acetyltransferase tissue-specific expression
and the influence of both genetics and environmental exposures on human N-acetyltransferase
tissue-specific mRNA and protein expression.

These objectives will be accomplished upon

completion of the following three specific aims: (1) Characterize the catalytic activity, substrate
specificity, and thermostability of Sprague Dawley rat N-acetyltransferase isozymes by
recombinant expression in Escherichia coli; (2) Characterize Natl and Nat2 mRNA and protein
expression in multiple tissues of different rapid acetylator rat strains; (3) Investigate the influence
of cigarette smoke inhalation on Natl and Nat2 mRNA and protein expression in multiple tissues
of different rapid acetylator rat strains.
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Specific Aim I
Introduction
Specific Aim I will characterize the catalytic activity, substrate specificity, and
thermo stability of Sprague Dawley rat N-acetyltransferase isozymes by recombinant expression
in Escherichia coli. While much of this aim was accomplished as described in chapters four and
five, further experiments were proposed for completion of the work. The methods described in
this section were not presented in chapter four or five, but will be utilized in addition to the
methods outlined in chapter four and five for completion of analyses related and unrelated to
Specific Aim I. Since a formal introduction to Specific Aim I can be found in chapters four and
five, an extensive introduction will not be repeated here.
The purposes of Specific Aim I are as follows: (1) Verify similarities in biological function
between rat and human N-acetyltransferases (suggested by high sequence identities) in an effort
to validate the rat as a suitable in vivo model for this research; (2) Sequence and characterize the
previously unidentified rat Nat3 and determine its relevance to this study.
The hypotheses that drive this aim are as follows: (1) Rat Nats are comparable to human
NATs with regards to catalytic activity, substrate specificity, and thermostability, and therefore
may serve an analogous physiological role; (2) Rat Nat3 is a functional N-acetyltransferase
enzyme, similar in function to Nat! and Nat2, nevertheless with distinct catalytic activity,
substrate selectivity, and thermo stability.
Methods

Colorimetric Determination of Enzyme Activity. Since HPLC assays are generally
developed only for commonly assayed substrates, a different assay will be utilized for the less
common substrates p-aminoacetanilide, 3-amino-4-methoxyacetanilide, 3-ethylaniline, 2-amino5-nitrophenol, 4-amino-2-nitrophenol, 2,6-dimethylaniline, o-toluidine, and 3,5-dimethylaniline.
Incubation of recombinant lysates with acetyl-CoA and substrate will be performed as described
in chapter five. Following incubation, guanidine HCI and sodium phosphate (pH 6.8) will be
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added,

followed

by

dithionitrobenzene

(DTNB),

sodium

phosphate

(pH

6.8),

and

ethylenediaminetetraacetic acid (EDTA) and incubation at room temperature for 5 minutes.
During these incubations, CoASH is produced by reaction of free CoA, a byproduct of the Nacetylation reaction and indicator of substrate conversion to product, with thiol-containing
DTNB, resulting in a yellow color that will be quantified using a Beckman DU-650
spectrophotometer to measure the absorbance of these samples at 412 nm (De Angelis et aI.,
1998). Control reactions containing no substrate will be included for each sample and each
dilution to control for the absorbance of the total protein present in the reactions. Dilution buffer
(homogenization buffer) must contain no dithiothreitol (DTT) or ~-mercaptoethanol since they
produce a yellow color that will interfere with absorbance readings.

Nmoles of acetylated

product is inferred by multiplying the absorbance at 412 nm by the CoASH molar absorption
coefficient 0.0137 (Riddles et aI., 1983). Activities will be calculated as nmoles/min/mg, and
kinetic parameters will be determined as described in chapter five.

Metabolic Activation Assay.

Metabolic activation assays measure the formation of

DNA-adducts from activated O-acetylation products (Figure 2).

These assays will use

recombinant bacterial lysates containing Nat1 13, Nat2 20, Nat2 21A, Nat2 2IB, Nat3, or the
PKK223-3 negative control (no insert). Various enzyme dilutions will be assayed initially to
determine the dilution necessary to ensure that < 15% total substrate concentration is consumed
during the reaction.

Cytosols will be incubated with 0.5 mM acetyl-CoA, 0.37 mM 2-

deoxyguanosine (Sigma) and 300 /lM substrate for 10 minutes at 37°C. Reactions will be stopped
by adding water saturated ethyl acetate to precipitate the protein. Precipitated protein will be
removed by centrifugation at 13,000 rpm for 10 minutes. Fifty III of the upper phase (organic)
will be transferred to an HPLC vial, without disrupting the interface, then the solvent evaporated
to dryness in a speed-vac for about 15 mintues. After drying, the adducts will be resuspended in
10% acetonitrile with vortexing and analyzed by high performance liquid chromatography
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(HPLC) using System Gold Software (Beckman-Coulter, Fullerton, CA, USA) for quantification
of N-acetylated product. Compounds to be tested include N-OH-PhIP and N-OH-ABP. Methods
for this assay were developed by Mark Doll. Data will be analyzed as described for the Nacetylation assays in chapter five.

Western Blot. Western blots will be performed on recombinantly expressed rat Nat2 20,
Nat2 21A, and Nat2 2IB in an attempt to confirm the small difference between the two slow
acetylator alleles (Figure 22). This will require use of a loading control. A re-probing step will
be added to the previously described Western blot protocol in chapter five,.

Instead of

normalizing to a bacterial housekeeping gene, a commercially available monoclonal antibody
against bacterial ~-lactamase (Abeam Inc., Cambridge, MA, USA) will be utilized. This antibody
was raised in mouse, whereas the Nat antibodies were raised in rabbit, thus the membrane can be
re-probed without a rigorous stripping protocol. Since ~-lactamase is expressed by the PKK2233 expression vector, this antibody will provide a way to directly normalize the Nat bands to the
level of PKK223-3 expression in each preparation.

The resulting protein bands will be

quantitated by densitometry and the Nat bands corrected relative to
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~-lactamase

as the standard.

Specific Aim II
Introduction
This aim will investigate the mechanism behind the tissue-specific expression of rat Nats,
which will lay the groundwork for aim three. As described in chapter one, little is known about
the in vivo mRNA and protein expression of rat Nat] and Nat2 in any tissue. Experiments are
proposed to analyze Nat expression in multiple tissues from multiple inbred rat strains to
characterize N-acetyltransferase expression and the influence of genetic variability (trans-acting)
on Nat expression. Only one publication to date reports rat Nat] and Nat2 mRNA sequences
(from pineal gland), and asserts that rat Nat] and Nat2 share a single promoter (Ebisawa et aI.,
1995). This is not the expected result of these proposed studies. In fact, Ebisawa's findings have
not been duplicated by other laboratories, or for other tissues, and are inconsistent with more
recent studies of human N-acetyltransferase expression (Husain et aI., 2004).

If, however,

Ebisawa's results are duplicated in other tissues, the regulation of rat Nats will still have
relevance for understanding the regulation of NAT expression with regard to promoter-dependent
mRNA splicing and tissue-specific expression.
Following exposure by ingestion, inhalation, or through the skin, many factors influence
the NATl and NAT2 mediated metabolism of arylamines including: (1) the combined NATl and
NAT2 genotypes, which determine rapid and slow acetylator status for each isozyme; (2) tissue-

specific NAT expression, which determines the tissue distribution of NAT 1 and NAT2 isozymes;
(3) the characteristic tissue distribution of each arylamine, which determines each tissue's level of
exposure to arylamine carcinogens; (4) Cytochrome P450 and other oxidation enzymes in each
tissue, which determines the fraction of activated arylamine carcinogen; (5) competitive
metabolism by other polymorphic xenobiotic metabolizing enzymes such as glutathione Stransferases (Meisel P, 2002). Combinations of these factors will no doubt influence DNAadduction and possibly mutagenesis.

DNA-adduct levels are a convenient gauge for the

metabolic conversion of aryl amine carcinogens to reactive species, and are directly relevant since
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DNA-adducts could be predictive of tumor incidence (Otteneder and Lutz, 1999). Therefore, in
vivo DNA-adduct formation following arylamine exposure in rats will be the criterion used to

prioritize the tissues selected for Nat expression analyses. This aim will focus initially on rat Nat
tissue-specific expression in lung, liver, pancreas, bladder, kidney, prostate (male only),
mammary gland (female only), and colon (Cummings et ai., 1994; Fretland et ai., 1997; Fretland
et aI., 2003; Kaderlik et aI., 1994).

Although enzymes other than N-acetyltransferases are

involved in activation of arylamines, the tissues listed above are among the most critical sites for
arylamine-induced cancer risk.

Since N-acetyltransferases catalyze the activation and

deactivation of arylarnines, these tissues demand the highest priority for a study related to Natmediated cancer risk.
In addition to tissue-specific expressIOn, this study will investigate the influence of
genetic variability (trans-genetic background) on Nat expressIOn.
polymorphisms

In

Since single nucleotide

the coding region, even polymorphisms that are silent in the amino acid

sequence, could influence Nat expression and compromise our ability to draw meaningful
conclusions from differences in the expression of different alleles (Capon et aI., 2004; Shen et al.
1999), only rapid acetylator rat strains will be chosen, each possessing the same Natl*13,
Nat2 *20, and Nat3 coding region sequences.

A number of rat strains were screened by

automated sequencing of the complete Natl, Nat2, and Nat3 coding regions. Since the inbred
strains used in this aim will not vary in their Nat genotypes, any variations in Nat gene expression
must be due to the influence of either cis- (outside the coding region) or trans-acting genetic
factors on rat Nat expression. Further experiments could allow distinction between cis- and transgenetic influence.
The specific purposes of this aim are as follows: (I) Quantify the expression of Nat 1,
Nat2, and Nat3 mRNA and protein in various rat tissues; (2) Characterize the use of differential

promoters and alternative splicing patterns in rat Natl and Nat2 mRNA expression, and observe
any associations with rat Nat tissue-specific expression; (3) Investigate the influence of genetic
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background on rat Nat expression by comparing Natl and Nat2 tissue-specific mRNA and protein
expression in different inbred rat strains.
The hypotheses that drive this aim are as follows: (I) Rat Nats are tissue-specifically
expressed with characteristic rnRNA and protein expression patterns for each tissue; (2) Nat
expression is tissue-specifically regulated through differential promoter usage and alternative
splicing of non-coding exons; (3) Cis- and/or trans-acting genetic factors may modify the
expression of rat N-acetyltransferases at the rnRNA and/or protein level.
Methods

Genotyping Rat Strains. Rat genomic DNA from various inbred strains was isolated
from blood samples (performed by Dr. David Barker) or ear clippings (performed by Mark Doll)
that were purchased from Charles Rivers Laboratories, Inc. (Wilmington, MA) and Harlan
Bioproducts for Science (Indianapolis, IN, USA). Natl, Nat2, and Nat3 were amplified from the
genomic DNA by duplicate PCR reactions using with high-fidelity Phusion polymerase
(Finnzymes).

The PCR primers used for amplification of Nat2 and Nat3 were described in

chapters five and four, respectively. The PCR primers used to amplify rat Natl (Forward, 5'ctggaattcatggacatcgaagcatacttcgaaaggattggttac-3'; Reverse, 5' -agagcatgcatggagacccaatttaccctaaatagt-3') were designed by Mark Doll.

Duplicate PCR reactions were combined, then PCR

products purified using the QIAquick PCR Purification Kit (Qiagen). Purified PCR products
were then run on a 1% agarose gel to verify the presence of PCR product. Following verification,
the purified PCR products were sequenced (top and bottom strands) by automated DNA
sequencing using the BigDye Terminator v l.l Cycle Sequencing Kit (Applied Biosystems), and
reaction products analyzed on an ABI 310 Genetic Analyzer (Applied Biosystems). Sequencing
primers were described in chapters V and IV for Nat2 and Nat3, respectively. Nat] sequencing
was carried out using the two primers mentioned above, plus five additional forward and reverse
primers

(Forward,

5' -tctgctgtactgggctctga-3',

5' -aagagaatggaacctggtac-3' ,

5' -

gcctctgtgtttgtaagcac-3'; Reverse, 5' -agaagacagtttgctttcta-3', 5' -acctggtaaagtgacgatat-3') designed
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by Mark Doll.
Of all the rat strains sequenced, PVG, MW, WF, DA, LoulM, CDF, BN, and LEW, in
addition to F344 and SPRD, possess the wildtype Nat allele at all three loci (Table 2). Strains
ACI and COP contained a new polymorphic Nat3 allele that will be submitted to GenBank upon
verification. The predominance of the original Nat3 sequence (A Y253757) among the rat strains
supports its designation as the wild-type Nat3 allele.

Rat Selection and Care. For the following analyses, male and female rats from six
different rat strains will be sacrificed without any prior experimental treatment.

To eliminate

variability in conditions with which the rats are raised, all rats will be ordered from Harlan
(Indianapolis, IN) to ensure that they are raised under the same conditions. Rats will be obtained
at an approximate age of 5 weeks, acclimatized to the University animal facilities for at least 5
days prior to sacrifice or exposure (see Specific Aim III). Rats will be housed in plastic cages
with wire bar tops. Ground corn cob bedding (1/4" deep) is changed at least two times a week.
Diet will consist of Purina Lab Chow #5001. Room temperature will be maintained between 7274°C and humidity between 40-70%, with light/dark cycles of 12 hours (lights on at 6 a.m. and
off at 6 p.m.).
All experiments will be replicated in four animals (per strain). The total number of
animals required for completion of this aim is approximately 48 (6 strains X 4 replicates X 2
sexes).

Rats will be sacrificed by exsanguination, making it possible to clear the rat tissues of

blood prior to harvest. According to the recommendations of the Panel on Euthenasia of the
American Veterinary Medical Association, death by exsanguination is an acceptable form of
euthanasia if the animal is anesthetized prior to the procedure (AVMA Panel on Euthenasia,
2001). To minimize the stress involved in administering anesthesia to the rats, the head will be
covered with a cloth or towel, providing a dark environment while also preventing the animal
from biting (Rassmussen and Ritskes-Hoitinga, 1999).

Exsanguination and Tissue Isolation. Rats will first be anesthetized by 1M injection of
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Nat3 (A Y353757)

Inbred Strain

Nat1*13

Nat2*20

ACI t

./

./

G619T

PVG

./

./

./

MW

./

./

./

WF

./

./

./

PETH

./

./

?

DA

./

./

./

LOU/M

./

./

./

CDF

./

./

./

BN

./

./

./

LEW

./

./

./

copt

./

./

G 619T

(F344)

( ./)

( ./)

( ./)

(SPRD)

( ./)

( ./)

( ./)

(NSD)

( ./)

(2*21B)

( ./)

(WKY)

( ./)

(2*21A)

( ./)

Table 2. N-acetyltransferase Loci Sequenced for Various Inbred Rat Strains
Rat Nat loci from various inbred rat strains were sequenced to determine their genotype.
Previously sequenced rat Nat loci from four other strains are also shown (parentheses). Of the above
inbred rat strains, 10 possess wild type Nat], Nat2, and Nat3 alleles (underlined) Two strains possess
identical polymorphic Nat3 alleles (t).
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approximately 1 ml/kg + 50 )11 ketamine HCL (800 mg)/xylazine HCl (120 mg) solution (Sigma)
(Flecknell P, 1996). Rats will then be sacrificed and exsanguinated by cardiac puncture. KrebsHenseleit bicarbonate buffer (Krebs et aI., 1932) saturated with a mixture of 95% O2 and 5% CO2
will be perfused into the aorta using a 16 gauge needle for 3 minutes at 30 ml/min.

The

ascending vena cava will be cut immediately following puncture to allow the blood to drain.
Lung, liver, pancreas, bladder, kidney, prostate (male only), mammary gland (female only), and
colon tissues will be harvested. Triplicate representative tissue sections will be isolated from
D

each tissue, then flash frozen in liquid nitrogen. Tissues will be stored at -80 C until further
processing, with the exception of pancreas tissue, which, due to its high levels of ribonucleases,
will be processed for RNA extraction immediately.
Initial

experiments

will

be performed to compare tissues

harvested without

exsanguination versus tissues that have been exsanguinated to determine whether blood Nat
expression contributes significantly to mRNA and protein quantification. Since the extent of
blood perfusion varies among tissues, blood could contribute to Nat expression measurements in
a disproportionate manner, resulting in an inaccurate measurement of tissue-specific expression.
RNA Isolation. Frozen tissue sections will be thawed in RNA STAT-60 (Tel-Test Inc.,
Friendswood, TX, USA) and disrupted for 1 minute in a bead-beater homogenizer. RNA will
then be isolated from the tissue homogenates according to RNA STAT-60 protocol.
Contaminating DNA will be removed from RNA using Turbo DNAlree (Qiagen). RNA will be
D

stored at -80 C. RNA will be analyzed for quality by electrophoresis on a 1% agarose gel. RNA
standards of known concentration will be run on the same gel as the samples, and will be used to
create a standard curve for quantification of RNA concentration.

Protein Determinations.

Frozen tissue sections will be thawed

In

ice-cold

homogenization buffer, then disrupted for 1 minute in a bead-beater homogenizer. Cell lysates
will then be centrifuged at 100,000 x g for 1 hour, and cytosol aliquots stored at -80DC. Total
protein concentration will be determined using the Bradford method (Bio-Rad).
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Measurement of Relative mRNA Expression. Although it was determined that Nat3
should not be included in expression studies due to its lack of relevance to human NATs and
relatively small contribution to N-acetylation activity, Nat3 will be included in initial
determinations of relative rat Nat mRNA expression in tissues.

This will enable further

characterization of the contribution of rat Nat3 to overall N-acetylation in rat tissues, and examine
the possibility that high Nat3 mRNA expression compensates for the low activity of rat Nat3
enzymes.
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) will be used to
synthesize cDNA from rat tissue total RNA. RT-PCR reactions without reverse transcriptase will
be performed as controls for DNA contamination. Natl, Nat2, and Nat3 mRNA levels will be
measured by locus-specific quantitative real-time RT -PCR, normalized to I8S ribosomal RNA
(Applied Biosystems), using TaqMan Universal PCR Master Mix from Applied Biosystems and
an ABI Prism 7700 sequence detection system (Applied Biosystems). A single set of primers
were designed to amplify of all three Nat loci simultaneously, and gene-specific fluorescent
probes for detection of relative levels of Nat l, Nat2, and Nat3 in the same sample (Figure 26).
PCR standards will be used to correct for differences among the three locus-specific
MGB probes in sequence recognition and cleavage properties. Primers that flank the real-time
PCR target region (Figure 27) were designed in order to amplify this region for creation of PCR
standards. With these primers, PCR amplification will be carried out using high fidelity Phusion
polymerase (Finnzymes), and PCR products then purified using the QIAquick PCR Purification
Kit (Qiagen). PCR products will be quantified, then dilutions made and analyzed by RT-PCR to
create a standard curve for quantification of Nat mRNA.
The relationship 2-LlCT will be used to convert CT values from inverse logarithmic to linear
scale, where

~CT

is the I8S ribosomal RNA CT subtracted from the Nat-specific CT from the

same sample. Control samples lacking reverse transcriptase and water controls (no cDNA) to test
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Rat Nat Locus Real-Time RT-PCR Primer and Probe Design

r-····1

5'

----1i-:;4;:::i=====--:;4;=====~.
j

Probe

3'

Rev Primer

Fwd Primer : III

-+--------------

3' ~4~----~
!

1..........1

388

5'
449

Natl ccAG ATGTGGGAGC CTCTGG~AA~TT
~~~~g~g~§~a~a~g~g.ATCAGC CTCAGGTGCCTGCcatctt
Nat2 ccAG ATGTGGGAGC

~~~~~~~g~g§~a~a~g~g~ATCAGC CTCAGGTGCCTGCcatctt

Nat3 ccAG ATGTGGGAGC CTCTGGAATT§ac tc~~aaggATCAGC CTCAGGTGCCTGCcatctt

Nat Reverse Primer

Nat Forward Primer

S ' -GCAGGCACCTGAGGCTGAT-3 '

S' - AGATGTGGGAGCCTCTGGAATT - 3'

Nan-Specific Probe <FAMl
S '- CTTCCCTGAGGTTAATT-3'
NaU-Specific Probe (VIC!
S' - CTTCCCTGATGTTAATTC-3'
Nat3-Specific Probe (TETl
S'-CTTTCCAGATGTCAATTC-3'

Figure 26_ Taqma n Primer and MGB Probe Design for RT-PCR Rat Nat Locus Discrimination
Nucleotide sequence comparison of rat Natl , Nat2, and Nat3 reveals regions of nucleotide identity
among the three loci surrounding a small region containing diffe rences among the loci (highlighted). Nonspecific Nat real-time PCR primers were designed based on the identical regions (capitalized). Locusspecific MGB f1uorogenic probes were designed to distinguish the three Nat loci based on the nucleotide
differences (underlined). Since the seq uence recog nized by the probes overlaps with the forwa rd primer
(dashed box), the probes were designed to recognize the opposite strand without overl apping the reverse
pn mer.
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for DNA contamination will be included.
Rat Nat mRNA Transcripts. The 5' RLM-RACE kit (RNA Ligase Mediated Rapid
Amplification of cDNA Ends) from Ambion will be used to characterize Natl and Nat2 mRNA
species in tissues of F344 strain inbred rats.

This is a superior method for determining the

complete 5' mRNA sequence because only mature. capped mRNA are amplified. Identification
of the 3' poly-adenylation site(s} will be determined using Ambion's 3' RACE kit, which
amplifies only mature, poly-adenylated mRNA. RACE products will be amplified by dual rounds
of PCR using locus-specific nested PCR primers (Figure 27) and RACE adapter-specific primers.
PCR products will be cloned using a pcDNA3.11V5-His Tapa TA Cloning kit (Invitrogen).
Clones will be used to transfect TOPIO E.co/i (Invitrogen). Plasmids will then be amplified by
growth in TOPIO E.co/i, followed by plasmid isolation using the Qiagen Plasmid Midi Kit.
Plasmid inserts will be sequenced using plasmid-specific T7 (Forward) and BOH (Reverse)
primers. If transcript length exceeds the range of these primers, new primers will be designed
based on the known transcript sequence. Sequencing data will be analyzed for transcription start
site and mRNA splicing patterns.

Transcript sequences will be submitted for publication in

OenBank.
Due to the cost of RACE analysis and the large numoer of samples to be analyzed, rat
strain F344 RACE results will be utilized to design Northern blot and RT-PCR analyses.
Heterogeneity in Nat mRNA transcript profiles among different strains will be determined by
comparison of the Nat transcripts by Northern blot. A high degree of variability in Nat transcript
sizes among rat strains will justify performing RACE experiments on strains other than F344. If
Northern blot analyses do not indicate such variability among strains, quantitative real-time RTPCR experiments can be designed using the F344 RACE data for quantification of the specific
transcripts detected.
Northern Blot.

Total RNA (15-20 ~g) will be separated on an agarose gel made from

NorthernMax lOX denaturing gel buffer (Ambion, Inc.) and run using NorthernMax running
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-C

-.-==
A
B
Rat Natl

E

:

j

.-==

~

F

~

0

ATGGACATCG AAGCATACTT -CGAAAGGATT
GGTTAs:AAGA ACTCA,aTGAA .!AA.GI.TGGAC TTGG~ACAT
TCTTCAACAC CAGATQC G~G Cagttccttt tgagaatctt agtatgcact GT~~GAAGC CATG~TCTG
CCACTTTTGA £CACAT~GT~ AGG~GC GGGGTGGGTG GTGTCTCCAG GTTAATCATC TGCTGTACTG
AAAATGGGTT TT~CCAC AATGTTGGGA GGATATGTTT A9-T~CTCC AGTCMCAAA TATAGCAGTG
CCT~TGGAAG

TCCTTTACTC TTGAGCCCCG
CfTCTGTGTT TmA,AGCACA TCQTT.£TGTT
AQTAGGAGAT TCAGTTATAA GGACAATGTA
GAAAACCACA TTTGGCATTT CTTTGGAGAA
AAAAATCTAT

CACTATTGAG GATTTTGAAT

CCTTgcagac c tcagaaggg
GATCTQGTTG AGTTTAAGAG
AAAG,!TTGTG CCCAAACATG

TAACTGAAQT
QGCTTAGAGG
GGCTCTGACC
AAATGGTCCA

CTCCT"tcAG:;A'l'G'l'QGGAG(l

CGTTTGACAG AAGAGAATGG MCCTGGTAC
CTCGGACCTC CTTGAAAAGA QCAAATATCG
ATGTAAATAC CTACCTTCAG ACATCGCCAG
gt t~CTGTT T~TTGG!TC CACCCTTACA
TCTGACTGAG GAAGAAATAG AAGATGTACT
G,£GA!C!CGT TTTTACTATT TAG

D 5' - cAAGGAACAGAACGATGTGCTTAC- 3'
E 5' - g cagacctcagaaggggtttg-3'
P 5' -GCCCAAACATGGCGAACT -3'

A 5'- TGGCCAAGTCCAACTTATTCACT- 3'
B 5'-agtgcacactaagattctc aaa aggaact -3'
C 5' - CGAGCagttccttttgagaatcttag- 3'

Rat Nat2
ATGGACATTG AAGCATACTT TGAAAGAATT GGTTATCAGA
TCTTCAACAC CAGATACGGG CTATTCC~TT TG~CTTG
.!:,ca..t.Qtttga tca~tt9t9 aGGAAGAAGC G,!GGTGG~TG
AAAATGGGCT TTGAAGCCAC AATGTTGGGA GGGTATGTCT

GTTCCAGGAA CAAACTGGAC TTGG~T TAACTGAAAT
AACATCCATT G~GGGGAAT C CATGGAGCTG AAtttaga~g
GTGTCTCCAG GTTAATCATC TGCTGTACTG GGCTCTGACC
TTAACACTCC AGCCAA,!AAQ TACAGCAGTG GCATGATTCA

~~~~~~~~~~~~~~~~~~~~~~~~ QGTTTGG"CG
TTCCT~A~
CGTTTGACAG AAGAGAATGG
AACCTGGTAC
~

~

TTGGACCAAA
AAAAATCTAT
CATCcrTGTT
TATAGGAGAT
GAAAAC!ATA

TCAGAAGAGA
TCCTTTACTC
TACAAG!A¥TCAGTTATAA
TTTGGGgttt

GCAGTATGTT
TTGAGCCCCG
TCATTTTGTT
GGACAATATA
cttt!;gagag

CCAAACCAAG
CACTATTGAG
CCTTGCAGAC
GATCTTGTAG
aaagcttgtg

AGTTTGTTAA
GATTTTGAGT
CCTAGAAGGG
AGTTTAAGAG
cc!:.AAACATG

A 5 ' - TCTGGTGTTGAAGAATTTCAGTTAATTC- 3'
B 5'-tcacaacttgatcaaagatgacttc taaat- 3 '
C 5'- CCATGGAGCTGAatttagaagtc a t -3'
Rat Nat3
ATGGACATTG AAG02TACTT TGAAAGAATT
ccttcagcat caga tacggg cTATCCCTTT
CCACTTTT~A TCACATTGTG ~GAAGAAGC
A~AT~GGTT TTGAQGICAC AATGTT~GGA
CCTTCTAfTA CAGGTGACCA TCAGTGGCAA

CA:

GGTTATCAGA
TGAGAACTTG
GGGGTGGGTG
GGATQTGTTT
AAAATATATT

00Il

CTCAGACCTC
.£C!TTAATAC
GTTCACTGTT
TCTGACTGAG
GTGATCGATT

CTTGAAAAGA
CTA!CTTCAG
TQGTTGGCTC
GAAGAAATAG
TTTTACfATT

ACAAATATCG
ACATCGCCAG
CACCCTCACT
AAGACGTACT

TAG

D 5' -GCGATGTCTGAAGATAGGTATTAATGG - 3'
E 5' - GTACTGAAAACTATATTTGGGGtttcttta -3 '
P 5' - tttctttagagagaaagcttgtgcct - 3'

AGTCCACGAA CAAACTGGAC TTG~CAT TAACTGAAAT
AACATCCATT GT~CC CATGGAACTG AGCTTAGAGG
GTGTCT,!C~ GTfAATCATC T,!CT!TACTG GGCTCTGACC
ATAGCfCTCC A!CClGCAAA
GTAGATAGTG CAT T~AT,!
C C~TTGACAG

~TGG~CAAA ~GA£A 8Q~T,!TGTT

CCAAACCAAG ~TT~TTQA !TCT~TTTI
AAAAATCTAf TCITTTACTC TTGAACCTCG ~CQATTG~ GATTT~AG~ ACGTGA§TQC ~TAC~CAG ~TC,!CC~
CATCTGT~T §AC~CACA TCACTTTGCT CCfTGCA!AC CCAAGAAGGG GT£C~TT TAGT~GG~C CAIICTTA! C
CAT~~T TC~TTATAA GGACAATGTA GATCTTGTGG AGTTTAAGAf TCTGAAGG~ GAAGAAATAG AAGAAGTCCT
GAA~CQT! TTTGGTATT~ ~TTGGAGAC AAAGCTTGTG CCCAAA~ GT~T!GGCT TTTTACTATT TAG
(A 5'- tgctgaaggATTTCAGTTAATGTTTG- 3')
(B 5' - gccc9tatctga ~gct9aa9g- 3'j
C 5' - CTCCAACCTGCAAATATAGCAACA - 3'

Locus -specifi c Base (S ingle)

D 5'- GTCTTTTAGTTTGTCCCAGATACCAAA -3'
( E 5' -GAAGAAATAGAAGAAGTCCTGAAGCG -3'j
( F 5' -GACAAAGCTTGTGCCCAAATG -3'j

r,psus _S pe c ific BaeA6

(Multiple )

•

Figure 27. Primer Design for Real-Time PCR Controls and PCR of RACE Products
Nested Primers A and B were designed for 5' RLM-RACE product PCR; E and F were designed for
3' RACE product PCR. Primers C and D, which encompass the real-time PCR target region (highlighted)
(Figure 26) will be used for creation of real-time PCR standards. Primer location is indicated by bold
and/or lower case text.
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buffer (Ambion, Inc.). RNA will then be transferred to BrightStar-Plus Positively Charged Nylon
Membranes (Ambion, Inc.) using NorthernMax One-Hour Transfer Buffer (Ambion, Inc.).
Probes will be labeled, hybridized, and detected using the North2South Direct Labeling and
Detection Kit (Pierce, Inc.). Nat RNA bands will be analyzed by densitometric analysis. Probes
specific to the Nat coding exon of the two Nat loci will be used identify locus-specific transcripts.

Quantification of Relative Protein Expression.

Western blotting will be used to

quantify the relative expression of Nat] and Nat2 protein in rat tissue cytosols. SDS-PAGE and
Western blotting will be carried out as proposed under Specific Aim I, normalizing to a-tubulin
as the internal control. For quantification, a correction factor will be calculated using purified
Nat proteins of known concentrations. This correction factor will be applied to the band intensity
for each isozyme to correct for differences in antibody concentration.

Nat enzymes will be

recombinantly purified using the IMPACT-CN Protein Fusion and Purification System (New
England Biolabs, Inc.).

In this system, enzymes are recombinantly expressed as fusion proteins

with a self-cleaving intein and chitin binding affinity tag. The affinity tag permits purification
using a chitin column, and the intein self-cleaves under reducing conditions (dithiothreitol)
leaving only the native enzyme. Enzyme concentration will be measured using the Bradford
method (Bio-Rad). The ECF detection kit (Amersham Biosciences, Inc.), in combination with a
Molecular Dynamics Storm 860 phosphorimager (Amersham Biosciences, Inc.) enables
quantitative measure protein bands directly from the membrane.

Dilutions of purified Nat

enzyme will be used to create a standard curve for quantification of protein from Nat band
intensities. These standards will be included on each gel.

Enzymatic Activity Assays. N-acetylation assays will be performed as described in
chapter five, but tissue cytosols will be used in the place of recombinant bacterial lysates.
Isozyme-selective substrates will be used to distinguish Nat] enzyme activity from Nat2 activity.
These substrates will be the most selective for each isozyme, as determined using the substrateselectivity data from Specific Aim I.
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Metabolic activation assays will be performed as described above under Specific Aim I
with substrates N-OH-PhIP and N-OH-ABP, but tissue cytosols will be used in the place of
recombinant bacterial lysates. The negative control will be a boiled tissue cytosol sample at the
same concentration as the normal tissue cytosols, since the activated arylamines will react with
protein and DNA.
Distinction of Cis- and Trans-Genetic Influence. Although not a primary goal, it may
be possible to distinguish between cis- or trans-acting genetic factors with an FI hybrid cross
between two strains that differ in their Nat expression. We can quantitatively measure the total

Nat mRNA for the locus of interest (locus "NatX") in the FI hybrid and compare with the
expression in both of the parent strains. If the total NatX mRNA in the FI hybrid is identical to
the total NatX mRNA in one of the parent strains, we can conclude that functionally important
dominant trans-acting genetic factors are influencing NatX expression in that parent strain. If,
however, the hybrid NatX mRNA level is intermediate between the two parent strains, we cannot
distinguish between cis-acting and trans-acting genetic factors.
Statistical Analyses.

Standard error of the means (SEM) will be calculated for

triplicate measurements of Nat mRNA expression, protein expression, and enzyme activity in
each tissue tested. Likewise, SEM will be calculated to test the variability of mRNA expression,
protein expression, and enzyme activity mean values for each tissue among four replicate
animals. Tukey parametric one-way analysis of variance will be performed to test the influence
of strain differences on expression in each tissue. This same analysis (Tukey) will be utilized to
analyze the differences among different tissues within each strain for significance of tissuespecific differences. This test compares every possible pair of measurements within the group for
significant differences, and eliminates errors associated with performing many individual t-tests.
Statistical significance will be determined at values of p < 0.05.
Potential Additional Analyses and Controls. If significant differences are found in the
expression of Nat loci among different strains, microarray analysis of tissue RNA from different
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rat strains could provide clues regarding biomolecular pathways that may be involved in Nat
regulation.

Since different strains typically model a specific pathology or trait, possible

differences in the regulation of Nat expression in these strains relative to other important gene
families could provide important information about the endogenous physiological function of Nat
and its connections to biomolecular pathways (Staudt and Brown, 2000; Le Roch et aI., 2003).
The Brown Cancer Center Microarray Facility provides equipment and expertise necessary for
successful rnicroarray experiments.

GeneChip Rat Genome 230 2.0 Array (Affymetrix, Inc)

provides comprehensive coverage of the rat genome, analyzing over 30,000 rat transcripts and
variants, and therefore is very useful for analysis of genetic variability and for comparisons of Nat
expression with the expression of other biomolecular pathways.

Potential Setbacks and Alternate Methods. In the event of failure to purify the rat Nat
isozymes using the IMPACT-CN system (New England Biolabs), two alternative methods are
available. Recombinant expression of tagged proteins can produce large amounts of protein that
are easily purified. Although purification of tagged proteins is relatively simple experimentally,
it is unclear whether the tag will alter native enzyme activity. Enzyme assays can be used to
determine the effect of a tag on enzymatic activity by comparing tagged enzyme Western blot
intensities and enzyme activities to recombinantly expressed Western blot intensities and enzyme
activities. If tagging the enzymes alters their activity, Western blot analyses of recombinant
expressions correlated to recombinant enzyme activity can be used to develop correction factors.
Correlation of quantified Nat protein to enzyme activity will enable quantification of active Natl
and Nat2 enzyme from enzyme activity assays with tissue cytosols, thereby also allowing
comparison of Natl and Nat2 active protein levels. Also, since detection of the purified enzyme
by Western blot does not require catalytically active enzyme, the tag should pose no threat to its
effectiveness as a standard for Western blot analyses. Tags should not interfere with the peptide
epitope used for production of the antibody. Alternatively, a synthetic peptide identical to the
peptide against which the anisera were produced can be used as an arbitrary standard for
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quantitation of the protein amount and the enzyme activity. Inability to quantify Nat protein and
inability to compare active Nat I and Nat2 enzyme are the major disadvantage of this approach.
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Specific Aim III
Introduction
This study will characterize the influence of one possible environmental influence,
cigarette smoke inhalation, on rat Nat mRNA and protein expression in multiple tissues. Humans
are regularly exposed to cigarette smoke either actively or passively.

If the components of

cigarette smoke influence NAT expression, the high prevalence of this exposure could be one
possible cause for variable NAT phenotypes in a population.

Cigarette smoke inhalation

influences the expression of a number of genes, including the induction of oxidative stressresponsive, Phase II-responsive, and Phase I-related genes (Gebel et aI., 2004; Roos et aI., 2003).
Since cigarette smoke contains many different compounds, this aim will not attempt to delineate
which chemicals influence Nat expression. The aim is simply to determine whether cigarette
smoke, as a single environmental exposure, influences Nat expression.
Cigarette smoke could be expected to influence Nat tissue-specific expression by several
mechanisms. Cigarette smoke could specifically influence lung Nat expression since the smoke
is introduced into the body directly through the lungs.

Smoke components could tissue-

specifically influence the expression of trans-acting genes that in tum influence Nat expression.
Cigarette smoke exposure could influence Nat expression in a strain-dependent manner due to
genetic background differences.

Any influence on Nat expression will most likely be very

complex, but it will not be the goal of this study to delineate the mechanism(s) of cigarette smoke
influence on Nat expression.
The specific purpose of this aim is to test whether cigarette smoke exposure influences rat
Nat] and/or Nat2 mRNA expression, protein expression, and/or enzyme activity in vivo. The

hypothesis is that cigarette smoke inhalation influences Natl and/or Nat2 mRNA and protein
expression in a tissue specific and/or strain specific manner.
Methods
Rat Studies. Male and female rats will be obtained and handled as described under
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Specific Aim II. Following the 5 day acclimatization period, rats will be exposed to cigarette
smoke, then immediately sacrificed as described under Specific Aim II. Completion of this aim
will require a minimum of 48 animals (6 strains X 4 replicates X 2 sexes).

Smoking Apparatus. A TE-lO fully automated smoking machine connected to two rat
exposure chambers large enough to hold four cages each (Teague Enterprises, Davis, CA, USA)
(Teague et aI., 1994) will be utilized to expose rats to smoke from filtered 2R4F research
cigarettes (Kentucky Tobacco Research and Development Center, University of Kentucky,
Lexington, KY). This cigarette was developed by the NCI Agricultural Research Service-USDA
and the Tobacco and Health Research Institute for delivery of approximately 9.2 mg of tar and
0.8 mg of nicotine. The NCI standard cigarette for experimental work, lR3F, is going out of
production. The TE-I0 smoking machine holds up to 30 cigarettes which it can automatically
load, light, puff, and discard. It can smoke up to 10 cigarettes simultaneously at variable flow
rates, thus providing multiple mechanisms for controlling smoke exposure rates. Chamber air
flow rates can be monitored and the contents of the air trapped on a filter for easy testing of the
composition and quantity of chemicals in the chamber air. For each experiment, one chamber
will be used for smoke exposure (4 rat cages) and the other chamber (4 rat cages) for a control
environment, with a maximum of four rats per cage.

Exposure Levels and Times. Rats will be exposed to a single 8 hour smoke exposure
without a recovery period. In the case that N-acetyltransferases are immediate response genes,
this time frame should be enough for de novo N-acetyltransferase protein synthesis. The animals
will then immediately be sacrificed for analysis of the influence of cigarette smoke on Nat
expression. This large initial exposure is designed to test for any possible influence of cigarette
smoke inhalation on rat Nat gene expression. If no effect is seen on mRNA levels, protein levels,
or enzyme activities following the 8 hour exposure, it could be an indicator that cigarette smoke
exposure does not influence Nat gene expression, or it could indicate that Nats are not immediate
response genes, and extra time is required for de novo synthesis of transcription factors. If no
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effect is observed at the mRNA level, a longer exposure (12, 24, 48 hours) or a longer lag time
between exposure and sacrifice may be necessary to allow time for de novo synthesis of
transcription factors.

Determination of Exposure Level and Exposure Effect on Health. Immediately prior
to exsanguination, a blood sample will be collected from each animal. A commercially available
enzyme linked immunosorbant assay (ELISA) will be used to measure serum cotinine levels
(Cozart Biosciences, Ltd, Oxfordshire, UK) as an indication of the smoke exposure of each
animal. Chamber smoke concentrations will be monitored during each exposure by weighing the
total filtered suspended particles from a known volume of air over a 5 minute period. Rat weights
will be recorded before and after exposure as a gauge the general health of the animals.

Measurement of Tissue mRNA and Protein Expression. The analyses described in the
previous section ("Specific Aim II") will be followed for analyses of tissue mRNA and protein
expression in smoke-exposed rats.

Since it is up-regulated in response to cigarette smoke

exposure in rats, CYP1Al mRNA levels will be measured in treated versus untreated rats as a
control for the effectiveness of our smoke exposure methods.

CYP1Al expression will be

measured by RT-PCR with the primers and probes designed as previously reported (Gebel et aI.,
2004).

Statistical Analyses. Standard error of the means (SEM) will be calculated for triplicate
mRNA, protein, and enzyme activity measurements in each tissue from four replicate animals for
each strain. Likewise, SEM will be calculated to test the variability of mean mRNA expression,
protein expression, and enzyme activity values for each tissue among four replicate animals.
Differences in mRNA expression, protein expression, and enzyme activity between treated and
untreated animals will be tested for significance using a t-test, since only single sets of data will
be compared. Statistical significance will be determined at values of p < 0.05.

Potential Additional Analyses and Controls. Microarray analysis of tissue RNA from
treated and untreated rats could aid in identification of genes with expression altered similarly to
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Natl and/or Nat2 in response to cigarette smoke components. This type of information could
provide clues toward determining an endogenous physiological function for Nat in addition to the
mechanism of Nat regulation (Staudt and Brown, 2000; Le Roch et a\., 2003). This information
would also validate the methods used here by giving a view of the overall affect of the cigarette
smoke exposure methods used, enabling comparison of the results to those found in similar
experiments previously reported in the literature (Gebel et a\., 2004). The Brown Cancer Center
Microarray Facility provides the equipment and expertise necessary for successful microarray
experiments. GeneChip Rat Genome 230 2.0 Array (Affymetrix, Inc) provides comprehensive
coverage of the rat genome, analyzing over 30,000 rat transcripts and variants.

Potential Setbacks and Alternate Methods. If no differences are detected between the
Nat] and Nat2 mRNA and protein expression/activity in treated versus untreated rats following

the initial exposure, we will conclude that cigarette smoke does not influence N-acetyltransferase
expression/activity in rat. This may provide opportunity to extend the analyses performed in
Specific Aim II or explore other environmental exposures.
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